Curriculum Vitae Jan Aileen Nolta, Ph.D
Total Page：16
File Type：pdf, Size：1020Kb
CURRICULUM VITAE – JAN AILEEN NOLTA, PH.D.
Date: March 12, 2010
PERSONAL INFORMATION
Sex: Female Place of Birth: Willows, California, 11/11/60 Citizenship: U.S.A.
ADDRESS AND TELEPHONE NUMBERS:
Business Address: Jan A. Nolta, Ph.D. University of California, Davis Room 2120, 2700 Stockton Blvd Sacramento CA 95817 Office: (916) 703-9308 FAX: (916) 703-9300 Websites: lab: www.jannolta.com
Program: http://www.ucdmc.ucdavis.edu/stemcellresearch
email address: [email protected]
Home Address: 4430 Woodson Ave. Sacramento, CA 95821 916-202-6080
PRESENT POSITION:
11/06 - present Professor, University of California, Davis Director, Stem Cell Program and Institute for Regenerative Cures Scientific Director, UC Davis GMP facility Department of Internal Medicine Division of Hematology/Oncology
EDUCATION:
1978 Willows High School, Willows, CA 1978-1984 California State University at Sacramento, Sacramento, California June 1984 B.S. Biology
Department of Molecular Genetics - classes taken toward Masters Degree 1984-87 University of California at Davis, Davis, California
1990-94 University of Southern California, Los Angeles, California May, 1994 Ph.D. Molecular Microbiology
Postgraduate Post-Doctoral Fellow, (Don Kohn, mentor), Childrens Hospital of Los Angeles, LA, CA,
1 May 1994- July 1997 ACADEMIC POSITIONS / PREVIOUS EMPLOYMENT:
3/ 02 – 01/07 Associate Professor of Medicine & Associate Professor of Pathology/Immunology, Washington University School of Medicine, Tenure granted September 2002.
12/03-3/07 Scientific Director, GMP Facility for Cell Processing and Gene Therapy-Washington University School of Medicine
7/97 – 3/02 Assistant Professor, University of Southern California School of Medicine, Department of Pediatrics, Los Angeles, CA.
8/98 – 3/02 Assistant Professor (secondary appointment), School of Graduate Studies, USC School of Medicine. Department of Developmental Biology, Los Angeles, CA.
1994 – 1997 Postdoctoral Fellow, John Connell Gene Therapy Foundation
1990 – 1994 Graduate Student, USC School of Medicine, Dept. of Molecular Microbiology.
1987 – 1990 Research Specialist II-IV, Dept. Research Immunology/ Bone Marrow Transplantation, Childrens Hospital Los Angeles, L.A., CA.
1986 – 1987 Cytogenetics Laboratory Intern, UC Davis Medical School.
1983 – 1987 Hematology Laboratory Technician/ Night Shift Supervisor, University of California, Davis Medical Center.
UNIVERSITY AND HOSPITAL APPOINTMENTS AND COMMITTEES:
2007 – present Scientific Director, University of California, Davis Good Manufacturing Practice (GMP) Facility 2003 – 2007 Scientific Director, Washington University GMP/Gene Therapy and Cell Processing Facility 2003 – 2006 Animal Studies Committee, Washington University 2000 – 2002 Chair, Institutional Biosafety Committee, Childrens Hospital of Los Angeles 2000 – 2002 Hospital Safety Committee, CHLA 1996 – 2002 Animal Care Committee, Childrens Hospital of Los Angeles 1997 – 2000 Intellectual Property Committee, Childrens Hospital Los Angeles 2000 – 2002 External Advisory Board, Seattle Cystic Fibrosis and Gene Therapy Programs 1999 – 2000 University of Minnesota External Review Board
MEDICAL LICENSURE AND BOARD CERTIFICATION: None (Ph.D.) MILITARY SERVICE: None
HONORS AND AWARDS:
1978 Honors at Entrance, CSU Sacramento 1978 Bank of America Scholarship 1978 Golden Key Honor Society 1978 – 1984 Dean's Honor List, CSUS: 3.85 GPA 1984 – 1984 UC Davis Graduate Honor List for masters courses: 4.0 GPA 1985 University of California Affirmative Action Scholarship
2 1990 - 1994 USC Graduate Honor List: 4.0 GPA 1988 – 1995 Awarded American Society of Hematology Travel Grants 1991 National Research Service (NRSA) Training Grant 1996 International Society of Experimental Hematology New Investigator Award 1997 Research Career and Development Award from the CHLA Research Institute 1997 James A. Shannon Award for New Investigators: National Institutes of Health 2008 Huntington’s Disease Society of America Distinguished Leadership Award 2009 Distinguished Service Award, California State University, Sacramento CA
EDITORIAL RESPONSIBILITIES
2008-present Associate Editor, Stem Cells
2000 – 2007 Editor: Gene Therapy Section: Leukemia
2002 – 2008 Editorial Board, Blood
2001 – 2007 Editorial Board: Experimental Hematology
2001– 2008 Editorial Board: Human Gene Therapy
1998 – 2000 Editorial Board: Leukemia
2002 – 2006 Editorial Board, Molecular Therapy
2005 - present Editor: Tissue/Organ Regeneration Section: Central European Journal of Biology (CEJB)
2001 – 2002 Section Editor, Leukemia: Spotlight on hematopoietic stem cells: looking beyond dogma
1994 – present Frequent reviewer of manuscripts for the following journals: BLOOD, Leukemia, PNAS, Experimental Hematology, Gene Therapy, Stem Cells, Biology of Blood and Marrow Transplantation, Human Gene Therapy, Molecular Therapy, Hematotherapy, FASEB, Journal of Clinical Investigation, Tissue Engineering, Journal of Experimental Medicine, Nature, Nature Medicine, Nature Biotechnology. Cell Stem Cell.
PROFESSIONAL SOCIETIES AND ORGANIZATIONS:
1978 – present Lifetime Member California Scholarship Foundation
1985 – 1987 Drosophila Molecular Genetics Club, University of California at Davis
1992 – present American Society of Hematology
1993 – present International Society of Experimental Hematology
1997 – present American Society of Gene Therapy
1997 – 1999 International Society for Hematology & Graft Engineering: Gene Therapy Committee
1998 – 2006 Membership: American Association for the Advancement of Science
3 1998 – 1999 Ad Hoc Member, NIH NIDDK Hematology 1 Study Section, (four sections attended)
1998 – 2003 Ad Hoc Member, NIH NIDDK Hematology 2 Study Section, (14 sections attended)
1998 – 2002 Norris Cancer Center, Developmental Therapeutics and Clinical Trials Research program
1999 Chaired/organized IBC Workshop on Stem Cell Gene Therapy, Lake Tahoe, Nevada
1999 NHLBI Gene Therapy Program Project Review Committee, Bethesda, Maryland
1999 Organized poster award session for LEUKEMIA journal at the ISEH meeting in Monaco, Monte Carlo
1999 NIDDK Program Project Reviews: Sickle Cell Anemia Gene Therapy Grants, NIH
2000 Grant Reviews: US Army breast cancer grants, Department of Defense, Virginia
2001 PO1 Program Project review and site visit, Baltimore, MD, October 10-12
2001, 2003 Italian Telethon Program grant reviews, Milan
2001 Program Project Review Session for the NIH NHLBI, Colombia, Maryland
2001 – 2005 Elected to the Nominating Committee: International Society of Experimental Hematology (ISEH) 2003 – 2005 elected chair of the ISEH nominating committee
1997 – 2007 Moderator/session chair (and abstract reviewer) at the Annual Meeting of the American Society for Hematology
1998 - 2007 Moderator/ session chair (and abstract reviewer) at the Annual Meeting of the International Society of Experimental Hematology (ISEH)
1999– 2002 Grant reviews for the Wellcome Society, London, UK
1999-2007 Moderator/session chair (and abstract reviewer) at the Annual Meeting of the American Society for Gene Therapy (ASGT)
2002 PO1 Program Project review and site visit, Baylor School of Medicine, Houston TX
2002 Grant reviews for the University of Washington in Seattle internal funding program
2002 Plasticity and Stem Cell Genome Anatomy RFA review: NIDDK, Bethesda MD
2003 Chair, NIDDK, NHLBI stem cell grant review sessions
4 2003– 2010 Hematopoietic Cell Gene Therapy committee, American Society of Gene Therapy
2004– 2006 Elected to Chair the ASGT Hematopoietic committee
2004 Chaired NHLBI grant review session: embryonic stem cells
2004 Chaired NIDDK study section for K08 trainee grants
2005 Chaired Embryonic Stem Cell review- K01, K08 and R21 supplements, NIH NHLBI
2005 January 10-11, Program project Review, Colombia MD
2003 – 2007 Full Member, Hematology study section- NIH
2005 January 11-13, Grant reviews for the American Cancer Society, Atlanta, GA
2005 March 18, Program project reviews, NIH, Bethesda MD
2005 April 20-21, Chaired P30 project review study section- Washington DC
2005 June 3, organized and chaired Educational Session on Human Gene Therapy Clinical Trial Results, American Society of Gene Therapy Annual Meeting, St Louis MO
2005 June 12-13, P01 Program project reviews, Bethesda MD
2005 July 22, Chaired review for Embryonic Stem Cell Supplements to existing NIH R01 Grants
2005 August 10-11, NIH Parent council for PO1 funding selection, Colombia MD
2006 May 22-23; NHLBI Cellular Therapy Strategic Planning Group
2007 April 17-18; project application review session, New Jersey Commission of Science and Technology 2007, Embryonic Stem Cell initiative, NJ
2007 April 20-21; Lung repair RFA review committee, Columbia MD
2007 July: completed 4- year tenure on Hematology Study section, NIH
2007 November 19; P01 Review Study Section (Teleconference)
2008 May 7 -8 COBRE reviews – training grants for under-represented Universities
2008 NIH special emphasis panels- 4 total, 2 chaired
5 2009 Nominating Committee, American Society of Gene and Cell Therapy
2009 Ad-hoc study section review panels for the NIH- 6 total including Two rounds of ARRA (Challenge) grant reviews
2010 PO1 reviews, NIH - cellular therapy program projects: National Institutes of Health, NIAD, “Immunomodulatory and Regenerative Effects of Mesenchymal Stem Cells on Allografts” Special emphasis Panel, Bethesda, MD, 1/26/2010. 2010 Conference grant reviews, NIH - teleconference.
2010 Chaired grant review study section, New York Stem Cell Initiative (NYSTEM) major facility grants. Reston, VA, 02/2010.
2010 Chaired NIH NIDDK program project reviews for Hematology Centers of Excellence, Bethesda, MD 07/26/10-07/27/10.
MAJOR INVITED PROFESSORSHIPS AND LECTURESHIPS:
Invited Presentations: International
1. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune deficient mice. Presented in the New Investigator Award Session, Plenary Symposium VII, at the International Society of Experimental Hematology 24th Meeting, Dusseldorf, Germany, Aug 30. 1995.
2. Engraftment of gene-modified cells from UCB in neonates with ADA deficiency. Presented at the Satellite Symposium on Somatic Gene Transfer and Gene Therapy in Malignancies, Dusseldorf, Germany, Sept 1, 1995.
3. Prospects for gene therapy via umbilical cord blood stem cells. Presented at the Symposium on UCB Transplantation, Pavia, Italy, October 19, 1995.
4. Stem cell transduction demonstrated by marking studies in immune-deficient mice and ADA- deficient neonates. Presented to the Department of Hematopoiesis and Cellular Biology, Institute Gustav Roussy, Paris, France, October 23, 1995.
5. Retroviral-mediated transduction of human hematopoietic stem and progenitor cells measured in a long-term xenograft assay. Presented at the European School of Hematology Conference; Vectors: from Biology to Technology, in Sitges, Spain, April 1997.
6. In vivo model to test improved methods for introduction of DNA into pluripotent human hematopoietic stem cells. Presented at the Tenth Symposium on the Molecular Biology of Hematopoiesis, Hamburg, Germany, July, 1997.
7. Modulation of the extent of retroviral-mediated transduction of human hematopoietic progenitors by positive and negative regulators of cell cycle. Presented at the Annual Meeting of the International Society of Hematology in Stockholm, Sweden, September, 1997.
6 8. Gene Therapy for ADA deficient Neonates. Presented at the Symposium on Molecular Hematopoieisis, Bormio, Italy, June 29, 1998.
9. Gene transfer into hematopoietic stem cells. Presented at the Symposium on Gene Therapy of the Hematopoietic System and CNS, in Lund, Sweden, September 12, 1998.
10. Impact of ex vivo culture conditions on hematopoietic stem cell cycle, transduction, and survival. Fifth International Conference on Gene Therapy and Molecular Biology, Heraklion, Crete, Greece, Aug 12, 1999.
11. Impact of ex-vivo transduction conditions on engraftment and gene marking, assessed in vivo. Presented at the Fourth International Symposium on Molecular Hematology, Frieberg, Germany, February 26, 2000.
12. Adhesion to the fibronectin fragment CH-296 maintains the protein levels of c-myb, GATA-2 and CD34, and modulates cell cycle progression in primary human hematopoietic progenitors. Presented at the 2001 meeting of the International Society of Experimental Hematology, Tokyo, Japan, August 25, 2001.
13. Detailed vector biosafety analyses in long term xenograft systems. Presented at the Multidisciplinary Forum on Regulation and Safety issues in Gene Therapy, Paris, France, June 11, 2003.
14. Human Hematopoietic Stem Cell Isolation and study in xenograft systems. Workshop: 34th Annual Scientific Meeting of the International Society for Experimental Hematology, Glasgow, Scotland, July 30, 2005.
15. Immunodeficient mouse models of human stem cell-mediated tissue repair, Keynote speaker: Robarts Vascular and Cell Biology Retreat, Ontario, Canada, March 28-30, 2007.
16. Human Stem Cells for tissue repair. Presented in conjunction with exchange graduate student Claus Sondergard's thesis defense, Aarhus University, Denmark, April 9, 2008.
17. Adult stem cells from umbilical cord blood and whartons jelly- role in tissue repair and revascularization. To be presented at the 20th Anniversary of the First Cord blood Transplant and 10th Anniversary of Netcord. European Society for Hematology, Eurocord, Netcord, EBMT, UT MD Anderson Cancer Center, Duke University International conference on biology and clinical applications of cord blood cells. Mandelieu, (Cannes), France. October 16-19, 2008.
18. Genetic engineering of mesenchymal stem cells. Keynote speaker, Japanese Society of Hematology, Kyoto Japan October 2009
19. Mesenchymal stem cells as a potential therapeutic for Huntington’s disease. Milan, Italy - November 11, 2009.
20. Non-hematopoietic uses of umbilical cord blood. In vitro Fertilization and cord blood banking symposium, Bregenz, Austria - November 14 2009.
7 21. Genetic engineering of Hematopoietic stem cells. Chang Gung Medical Foundation, Kaohsiung Branch. Taipei, Taiwan, March 17, 2010.
22. Stem cells for tissue repair. Taichung Veterans General Hospital, Taipei, Taiwan, March 18, 2010.
23. Non-hematopoietic uses of umbilical cord blood. NTUH International Convention Center; Room 401. Taipei, Taiwan, March 18, 2010.
24. Non-hematopoietic treatments using umbilical cord blood. Macau, March 19, 2010
25. Tissue repair using umbilical cord and placental stem cells. To be presented, Stem Cell Applications in Gene Therapy Symposium, Sheraton Tower, Hong Kong China, March 21, 2010.
26. Keynote lecture at The International Stem Cell Symposium Young Investigators Award Session – “the future of regenerative medicine”. To be presented in Seoul, Korea October 2, 2010.
Invited Presentations: National
1. Retroviral vector-mediated gene transduction of human bone marrow in vitro. Presented to the Division of Pediatric Oncology, Johns Hopkins Medical Center, Baltimore, MD, August 1990.
2. Effects of MGF on retroviral vector-mediated gene transfer into primitive hematopoietic progenitors. American Society of Hematology, 33rd Meeting, Denver CO, December 1991.
3. Glucocerebrosidase gene transduction of cultured Gaucher marrow. Presented at the International Society for Experimental Hematology, 21st Meeting, Providence RI, July 1992.
4. HGF to increase retroviral vector-mediated gene transfer into CD34+ human bone marrow cells. Conference on Stromal Regulation of Hematopoiesis, Bethesda, Maryland, 1992.
5. Co-transplantation of human marrow stromal cells producing IL-3 with CD34+ progenitor cells supports persistent human myelopoiesis in immunodeficient mice. Presented at the American Society of Hematology, Thirty-Fourth Annual Meeting, Anaheim, CA, December 1992.
6. An in vivo model of Human Gene Therapy. Presented at the Symposium on Hematopoietic Stem Cell Purification and Biology, Rockville, MD, 1993.
7. Transduced human CD34+ progenitor cells engraft in immune deficient mice: a model for human gene therapy. Presented at the Conference on Recent Advances in Hematopoietic Stem Cell Transplantation - Clinical Progress, New Technologies and Gene Therapy, San Diego, CA, March 1993.
8. In vivo system to assess the efficiency of retroviral-mediated transduction of primitive human hematopoietic progenitors. Presented at the American Society of Hematology, Thirty-Fifth Annual Meeting, St. Louis, MO, December 1993.
8 9. In vivo system to assess efficiency of Clinical Gene Therapy Transduction Protocols. Presented at the First Conference on Stem Cell Gene Therapy: Biology and Technology, Rockville, MD, September, 1995.
10. FLT3 ligand preserves viability of human hematopoietic stem cells during in vitro transductions. Presented at the American Society of Hematology, 37th annual meeting, 1995.
11. Retroviral - mediated transduction of pluripotent human stem cells verified by clonal analysis after differentiation in immune deficient mice. Presented at the American Society of Hematology, 37th annual meeting, 1995.
12. Proviral integration site analysis of marked human hematopoietic stem cells engrafted long-term in immune deficient mice. Presented at the Keystone Symposium on Hematopoietic Stem Cell Gene Therapy. Taos, New Mexico, February, 1996.
13. Stromal cells engineered to produce cytokines support multilineage human hematopoiesis in immune deficient mice. Presented at the Keystone Symposium on Hematopoietic Microenvironment, Taos, New Mexico, February, 1996.
14. High efficiency transduction of human CD34+ progenitors on fibronectin CH-296 verified by clonal integration analysis. Presented in the session on receptors at the 25th Meeting of the International Society for Experimental Hematology, Sheraton, New York, August 1996.
15. Genetic correction of hematopoietic stem cells. Presented at the TIGR Genomic Science Series Conference on Gene Therapy, Hilton Head Island, SC, May 1996.
16. Human cytokine production from engineered stromal cells influences lineage development from co- transplanted human CD34+ progenitors. Presented in the New Investigator Award Session at the 25th Meeting of the International Society for Experimental Hematology, Sheraton, New York, August 1996. (Awarded first place in the competition).
17. Alternate sources of hematopoietic stem cells. Presented in the Plenary Session at the American Society of Blood and Marrow Transplantation Scientific Meeting, San Diego, CA, October 1996.
18. Effects of ex-vivo transduction protocols on maintenance of the clonogenic capacity of primitive human hematopoietic cells. Presented at a scientific seminar at Systemix, INC. Palo Alto, CA, December, 1996.
19. Comparison of human hematopoietic progenitor content and retroviral marking in immune deficient mice transplanted with CD34+ vs. CD34+/38- cells. Presented at the 38th Meeting of the American Society for Hematology, Orlando, FL, December 1996.
20. Effects of TGFB neutralization on transduction and expansion of human hematopoietic cells. Presented at the Keystone Symposium on Hematopoiesis, Tamarron, CO, February 1997.
21. Molecular mechanism of TGFB-mediated quiescence in human CD34+ progenitors on fibronectin. Presented at the Keystone Symposium on Signal Transduction by Cell Adhesion Receptors, Keystone, CO, March 1997.
9 22. A system to measure the extent of human hematopoietic stem cell marking by retroviral vectors. Presented at the Annual Meeting of the International Society for Hematotherapy and Graft Engineering (ISHAGE) in Mission Bay, April, 1997.
23. Engraftment of human bone marrow progenitors in immunodeficient mice. Presented to the Scientific Advisory Board of Biotransplant, Inc., Charlestown, MA, October 1997.
24. The Effects of ex-vivo Manipulation on the Differentiation of Human Hematopoietic Stem Cells, Measured in an in vivo Xenograft System. Presented to the American Association of Blood Banks, Denver, Colorado, Oct 1997.
25. Induction of cell cycle entry by decreasing levels of the cyclin-dependent kinase inhibitors p15INK4B and p27 KIP1 in quiescent hematopoietic progenitors. Presented at the Meeting on the Cell Cycle, Keystone, Colorado, March 1998.
26. Effects of adhesion and cell cycle modulation on survival and retroviral-mediated transduction of hematopoietic progenitors. Fred Hutchinson Cancer Research Center, Seattle, WA, April 27, 1997.
27. Impaired activation of human T lymphocytes recovered from bnx/hu mice in response to either anti- CD3 + anti-CD28 antibodies or to PMA + ionomycin. Presented at the Keystone Symposium on transplant tolerance and rejection, Lake Tahoe, CA, 1998.
28. Xenograft models of gene therapy. Speaking and chairing/ organizing the workshop: IBC’s 4th international conference on hematopoietic stem cells, Lake Tahoe, Nevada, June 28-29, 1999.
29. Ex-vivo culture of human hematopoietic stem cells. National Institutes of Health ex-vivo Expansion Workshop, Bethesda, Maryland, July 21, 1999.
30. Xenograft models to assess vector safety. University of Kentucky Symposium on Biosafety, Lexington, Kentucky, October 22-24, 1999.
31. Engineering and transplantation of human mesenchymal stem cells. Presented at the Weekly Scientific Seminar Series, Osiris Therapeutics, Inc. Baltimore Maryland, May 1999.
32. An increase in the levels of transduction of engrafting human hematopoietic stem cells can be obtained by manipulating the cell cycle. Fourth Annual Human Gene Medicine Symposium, Department of Radiation Oncology, UCLA School of Medicine, June 14, 1999.
33. The bnx/hu xenograft model of human hematopoiesis. Presented at “Super Friday” Scientific Symposium prior to the Annual Meeting of the American Society of Hematology, New Orleans, Louisiana, Dec. 3, 1999.
34. Factors affecting human hematopoietic stem cell engraftment following ex vivo manipulation. Presented to the scientists, staff and members of the Lindsey F. Kimball Research Institute of the New York Blood Center, May 11, 2000.
35. Comparison of xenotransplantation models to study human stem cells. Presented at the “Super Friday”
10 Scientific Symposium prior to the Annual Meeting of the American Society of Hematology, San Francisco, CA, Nov. 30, 2000.
36. Mouse xenograft models to study human hematopoietic stem cell biology and gene therapy. Presented to the Department of Oncology, Washington School of Medicine, St. Louis, Mo, April 24, 2001.
37. Clonal analysis and immune deficient mice: tools for human hematopoietic stem cell plasticity research. Presented at the Stem Cell Plasticity Meeting, Santa Barbara, CA, May 5, 2001.
38. Extrathymic human T lymphocyte development: is there a link to autoimmunity? Presented at the symposium on Hematopoietic Stem Cell Therapy in Autoimmune Diseases, City of Hope Medical campus, Duarte, CA, October 4, 2001.
39. Immune deficient mouse models to study human stem cells. Presented at the Conference; In Utero Stem Cell Transplantation and Gene Therapy, Reno, NV October 28-30, 2001.
40. Cell cycle manipulation to enhance retroviral marking and clonal analysis: tools to study human stem cell plasticity. Presented at the Annual Stem Cell Gene Therapy Symposium organized by George Stamatoyannopoulis, Bethesda MD, March 2002.
41. Immune deficient mouse models: state of the art. Presented in an Educational symposium at the Annual meeting of the American Society of Gene Therapy in Boston MA, June 5, 2002.
42. CD34 expression is reversible on engrafting human stem cells. Presented in a simultaneous session at the Annual meeting of the American Society of Gene Therapy in Boston MA, June 8, 2002.
43. Xenograft models of human stem cell plasticity. Presented at the Symposium on Stem Cell Transplantation held in honor of the retirement of Dr. Robertson Parkman, Pasadena, CA, June 14, 2002.
44. Hepatocyte Growth Factor Increases Human Albumin Expression in the Livers of Immune Deficient Mice Transplanted with Highly Purified Human Hematopoietic Stem Cells. Presented at the Annual Meeting of the International Society of Experimental Hematology, Montreal, Canada July 8, 2002.
45. Xenograft models of human hematopoietic and mesenchymal stem cell plasticity”. Presented at the Clinical Research Division Seminar, Fred Hutchinson Cancer Center, Seattle, WA, November 4, 2002.
46. The use of immune deficient mice for studies of human hematopoietic and mesenchymal stem cell homing and plasticity. Presented at the Gene Therapy Tuesday Seminar Series at Baylor College of Medicine, Houston TX, December 17, 2002.
47. Xenograft models of tissue regeneration from human stem cells following injury. Presented to the Los Angeles Division of Pulmonary Medicine and Lung Development, University of Southern California, February 27, 2003.
48. Progress toward optimizing immune deficient mouse models for human hematopoietic and mesenchymal stem cell homing and plasticity. Presented at the Herman Wells Center for Pediatric Research, Indianapolis, Indiana. March 12, 2003.
11 49. Xenograft models to study human stem cell biology and gene transfer. Presented at the Educational Session at the Annual meeting of the American Society of Gene Therapy, Washington DC, June 5, 2003.
50. A novel model for tracking human mesenchymal stem cells in vivo, independent of surface protein expression. Presented at the Annual Meeting on Non-Hematopoietic Stem Cells, New Orleans, LA, September, 2003
51. Models to study human stem cells. Presented at the Scientific Symposium at the Annual Meeting of the American Society of Hematology, San Diego, CA, Dec. 2003.
52. Adult stem cell plasticity: hype or hope? Presented at Hematology grand rounds, Yale University, May 2004.
53. Novel cell sorting and transduction methods, studied in immune deficient mouse xenograft models. Presented at Grand Rounds, University of California, Davis, June 2004.
54. Cell cycle manipulation to increase transduction efficiency. Presented at the Educational Session at the Annual meeting of the American Society of Gene Therapy, June, 2004.
55. Research toward the use of adult stem cells for liver regeneration. Presented at the TechConnect Forum at the St. Louis Science Center, October 13-14, 2004.
56. Stem cells for tissue repair: update. Presented to the Arnold Rotary Club, St. Louis, MO December 15, 2004.
57. The NOD/SCID/MPSVII mouse model to rapidly localize transplanted stem cells of any type. Presented at the annual meeting of the Midwest Blood Club, Louisville Kentucky April 8 – 11.
58. Mesenchymal stem cells: dissection of phenotype vs function. Presented to RFA grantees and NIH officials, Bethesda, MD April 22, 2005.
59. Human Hematopoietic Stem Cell Isolation. Presented at the 2005 meeting of the Pediatric Academic Societies, Washington DC, May 14, 2005.
60. Immune Deficient Mouse Models to Study Human Hematopoietic and Mesenchymal Stem Cell Engraftment and Tissue Repair. Presented at Grand Rounds, University of California, Davis, Sacramento, CA, June 23, 2005.
61. Adult vs. Embryonic Stem cells for Tissue Repair; an overview. Presented at Hematology Grand Rounds, Case Western University, Cleveland Ohio, September 21-23, 2005.
62. The use of Aldehyde Dehydrogenase Enzyme as a method to isolate human progenitors capable of reconstitution of the hematopoietic system and tissue repair. Presented at the Annual Meeting of the Clinical Cytometry Society, Savannah, GA, October 16-19, 2005.
63. Human Stem Cell -Mediated Tissue Repair. Presented at the 4th Annual Gene Therapy Symposium
12 for Heart, Lung, and Blood Diseases (organized by Alice Tarantal and UC Davis), November 16-19, 2005.
64. Myeloid Cells vs. Mesenchymal Stem Cells for tissue repair strategies. Presented at the Myeloid Workshop organized in conjunction with the Annual Meeting of the American Society of Hematology, Atlanta, GA, Dec. 9 – 13, 2005.
65. Working toward cellular therapies using human umbilical cord blood. Presented at grand rounds, division of Hem/Onc, St. Louis University school of Medicine, St. Louis, MO, Jan. 30 2006.
66. The central roles of SDF-1 and HGF in ischemic wound repair by adult stem cells. Presented at grand rounds, University of Louisville, KY, March 29, 2006.
67. Nanoparticle Technology for tracking human stem cells into areas of ischemic tissue damage in immune deficient mice. Presented at the Annual Meeting of the American Society of Gene Therapy, Baltimore, MD, June 2, 2006.
68. Adult vs embryonic stem cells in tissue repair; issues surrounding the Missouri Stem Cell Initiative. Presented to the Medical Faculty of Washington University, October 2006.
69. Human stem cells for tissue repair: state of the art. Presented at the 4th annual retreat, Center for Biophotonics Science and Technology, Squaw Valley, CA, July 12, 2006.
70. Embryonic stem cells- the hype, the controversy, and the facts. Presented at the Chautauqua Country Club, Chatauqua IL, July 23, 2006.
71. Spotlight on Peripheral Vascular Disease: treating damaged blood vessels. Presented at the CIRM patient spotlight prior to the April 10th meeting of the ICOC, Sacramento, CA, 2007.
72. Working toward stem cell therapies for patients of all ages. Presented update on Stem Cell Program to the Basic Science Council, UC Davis, March 14, 2007.
73. Stem Cell Program/CIRM update. Presented, with Dr. Pomeroy, to the Board Of Visitors, UC Davis March 20, 2007.
74. Meet the investigator session, Annual meeting of the American Society of Gene Therapy, Seattle, WA, June 2007.
75. Human adipose-derived mesenchymal stem cells in tissue repair. Presented at the International Conference on Adult Mesenchymal Stem Cells in Regenerative Medicine, Cleveland Ohio, August 27, 2007.
76. The Future of Stem Cell Therapies: Presentation for Regional Students & High School Teachers, Lecture, UC Davis, NIH Training Program in Biomolecular Technology, Medical Education Department, Sacramento, CA, 09/29/2007.
77. An important dialogue on Stem Cell Research. Presented lecture and participated in panel discussion, for students, faculty, and community members in Dean’s Lecture Series, November 29, 2007.
13 78. Human stem cells for tissue repair, studied in xenograft models. Keynote presentation delivered at the Childrens Hospital of Los Angeles Saban Institute Annual Research Symposium, 11/28/07.
79. Dialogue on Stem Cell Research, Lecture/Panel Discussion, UC Davis Dean’s Lecture Series, Sacramento, CA, 11/29/2007.
80. Miltenyi Biotec: Human stem cell sorting for tissue engineering, Sacramento, Hyatt Regency 1/23/2008.
81. “Stem Cell Research in California’s Capitol City”, Presentation, Cell and Molecular Biology Course BIO 186A, California State University, Department of Biological Science, Sacramento, CA, 02/11/2008.
82. American Society for Bone marrow Transplantation (ASBMT) Annual Meeting: spoke and organized/chaired session: The Role of Adult Stem Cells from Bone Marrow and Cord Blood in Regenerative Medicine, 2/16/2008.
83. The College of Arts and Sciences: Health & Science Horizon: Exploring the Nuances and Breadth of Biomedical Science: Stem Cells: Is the Ethical Controversy Justified by Promising Science? UC Santa Clara, 03/04/2008.
84. Stem Cell research Impact on Senior Citizens, Presentation, PEO Women’s Group, Sacramento, CA, 04/25/2008.
85. “Human Cancer vs. Normal Stem Cells”, Speaker, Grand Rounds, Rochester University, Cancer Center Grand Rounds, Rochester, NY, 05/14/2008.
86. Human stem cell xenograft models for tissue repair. Presented at the Annual Conference on Humanized SCID Mouse Models: Stem Cells, Cancer, & Viral Pathogenesis, SUNY Upstate New York, Belhurst Castle, 5/15/08.
87. Human Stem Cells for Tissue Repair: Gene Marking, Tracking and Safety. 13th Annual UCLA Human Gene Medicine Symposium. 5/23/2008
88. Human Stem Cells for the Repair of Disease and Tissue Injury. UCDMC Pathology Department Grand Rounds. 06/02/08
89. Sixth Annual International Umbilical Cord Blood Transplantation Symposium. Human ALDH hi cells for liver repair, Los Angeles CA. 6/5/2008
90. Human cord blood ALDH hi stem cells to repair the liver. Ethics of Cellular Therapy Conference, sponsored by the Duke University CTSC. Washington Duke Inn, Raleigh-Durham, SC. 06/16/08.
91. “Adult Stem Cell Engineering to Combat Huntington’s Disease”, Presentation, Huntington’s Disease Society of America Northern California Chapter, Palo Alto, CA, 08/11/2008.
14 92. The Emerging Evidence for Cancer Stem Cells. Presented at the annual meeting of the American College of Surgeons, San Francisco, CA, 10/13/08.
93. “Under the Microscope”, Presentation, Sacramento State, Center for STEM Excellence, Sacramento, CA, 02/24/2009.
94. Stem Cell Therapies: Options for Avoiding Immune Rejection”, Presentation, UC Davis Department of Immunology, Genome Biomedical Facility, Davis, CA, 02/24/2009.
95. “Stem Cell Research for HD at UC Davis” and Introducing Scott Olson, Postdoctoral fellow, Nolta lab -2009 Award Recipient, Mentor/Sponsor, Introductory Lecture, Hunting Disease Society of American Seventh Annual Sacramento Celebration of Hope Dinner, Sacramento, CA, 02/26/2009.
96. “Stem Cells and Musculosketal Research”, Presentation, UC Davis Medical Center, Department of Orthopedics, Sacramento, CA, 04/07/2009.
97. Novel Stem Cell Therapeutics for Neurodegenerative Diseases, Presentation/Host Session, UC System-Wide Technology Transfer Forum in partnership with British Consulate-General, San Francisco-Burlingame, Ca, 04/15/2009.
98. “Overview: Stem Cell Program at UC Davis”, Presentation/Hosted Symposium, Collaborative symposium with the British Consulate visitors, Sacramento, CA, 04/15/2009.
99. Cancer as a Process: Special Study Module for Medical Students “Cancer Stem Cell Research”, Lecture/Class, UC Davis, Department of Hematology/ Oncology, Sacramento, CA, 04/17/2009.
100. “Stem Cell therapies: Bench to the Bedside”, Presentation/Grand Rounds, University of Reno, NV, 04/21/2009.
101. Emerging challenges in Microbiology and Immunology, “Stem Cell Therapies: Avoiding Immune Rejection”, Presentation, UC Davis, Department of Medical Microbiology & Immunology, Davis, CA, 04/24/2009.
102. Interview with Comstock Magazine, “Go Forth and Multiply”, Interview/Photo shoot, UC Davis Stem Cell Program, Sacramento, CA 04/27/2009.
103. Distinguished Service Awards-Distinguished Alumni of the Year, “Collaborations between UCD and CSUS”, Award/Address, California State University, Sacramento, Sacramento, CA, 04/30/2009.
104. “The Hope of Stem Cell Therapy in the Treatment of Huntington’s Disease”, Presentation, HDSA, Northern California Chapter Convention, Sacramento, CA, 05/02/2009.
105. “Using Immune Deficient Mice to Advance toward Clinical Trials of Stem Cell Therapy”, Presentation at Grand Opening Event, Jackson Laboratory-West Sacramento, CA, 05/05/2009.
106. “An Honest Conversation about Stem Cell Research” Presentation, Roberts Family Development Center, Del Paso Heights, Sacramento, CA, 05/11/2009.
15 107. Stem Cell dialogues, “Stem Cells in Neurodegenerative Diseases” Presentation, UC Davis Dean’s Lecture Series, Sacramento, CA, 05/12/2009.
108. Teen Biotech Challenge 2009 Biotech Symposium Awards Banquet, “Science is Cool!” Keynote Speaker, UC Davis, Freeborn Hall, Davis, CA, 05/22/2009.
109. “Synergisms for Stem Cell Research between Humans and Animals, Outlook for the use of Induced Pluripotent Stem Cells in Regenerative Medicine”, Presentation, Alamo Pintado Equine medical Center, Los Olivos, CA 06/20/2009.
110. “Stem Cell Research & Angiogenesis: How We Grow New Blood Vessels”, Presentation, Society of Vascular Nursing, UC Davis Medical Center, Medical Education Building, Sacramento, CA 06/22/2009.
111. “An Honest Conversation about Stem Cells including Present and Future, Therapies”, Guest Speaker, Rotary Club, Auburn, CA, 08-11/2009.
112. “Bladder Cancer Stem Cells”, Hematology Oncology Journal Club, Coordinator, UC Davis, Hematology Oncology, Sacramento, CA 09/04/2009.
113. “Stem cell therapies in diseases that affect older adults”. Mental Health Older Adult Committee, Lecture/Presentation, South Sacramento, CA, 09/8/2009.
114. “Clinical trials of stem cell and gene therapies” UC Davis Community Forum, Presentation, UCD Cancer Center, Sacramento, CA 09/9/2009.
115. “Neurodegenerative diseases”, Stem Cell Dialogues Community Seminar Series, evening presentation, UC Davis Cancer Center Auditorium. 09/10/2009.
116. “Human Stem Cells and Neurodegenerative Diseases”, Plenary speaker. ISCT Somatic stem cells: Innovations in Cord Blood & MSC Therapies, Conference, ISCT Meeting, Bethesda, MD, 09/15/2009.
117. “Induced Pluripotent Stem Cells Derived from Umbilical Cord Blood”. ISCT Somatic stem cell conference: Spoke in and Chaired session on Innovations in UCB Therapies, ISCT Meeting, Bethesda, MD 09/14/2009.
118. Stem Cell Awareness Day, “Stem Cells: From the Bench to the Bedside”, Presentation, Arthur A. Benjamin Health Professions High School, Sacramento, CA 09/23/2009.
119. Stem Cell Awareness Day, “Stem Cell Research for Huntington’s Disease at UC Davis”. Lecture at UC Davis CTSC Conference Center and laboratory tour, Sacramento, CA 09/23/2009.
16 120. STEM Excellence, Stem Cells for Healing Injury and Curing Disease-Future Therapies”, Keynote Speaker 3rd Annual Expanding Your Horizons Conference, Sacramento State University Campus, Sacramento, CA, 10/10/2009.
121. “Cancer stem cell research at UC Davis”. UC Davis Cancer Center, External Advisory Board Meeting, Cancer Stem Cell “Developing” Program, Speaker, Sacramento, CA 10/15/2009.
122. “Non-hematopoietic uses of cord blood” Pacificord, Lecture, Newport Beach, CA 10/17/2009.
123. “Stem Cell Research”. Keynote Speaker, Western Regional SNM Conference Nuclear Medicine Meeting, Monterey, CA, 10/30/2009.
124. “Cancer Stem Cell Research at UC Davis: Overview” Focusing on Cancer, Stem Cell Dialogues Community Seminar Series, UC Davis MIND Institute, Sacramento, CA, 11/04/2009.
125. “The Future of Fighting Disease”. California State University, Sacramento, Community Lecture, 11/17/2009.
126. “Working Toward Mesenchymal Stem Cell Therapy for HD”, Keynote Address, 3rd Annual Huntington’s disease Clinical Research Symposium, Baltimore, MD, 11/21/2009.
127. "Human stem cells: from the bench to the bedside", Keynote lecture, CSUPERB meeting for California State University students and teachers, Santa Clara CA, 01/08/10.
128. “Mesenchymal stem cell therapies for neurodegenerative diseases”. Presented at the Stem Cells World Congress, Burlingame, CA 01/21/2010.
129. “Update on Huntington’s disease research”. Presented to the Northern California Chapter of the Huntington’s disease society of America, 01/30/2010.
130. “Update on stem cell clinical trials - ongoing and planned - at UC Davis”. Presented to the translational group at the monthly meeting, UC Davis Cancer Center, Sacramento, CA 02/05/2010.
131. “Stem Cell Research from the Bench to the Bedside” Speaker/Presentation, California Association for Medical Laboratory Technology, Sacramento, CA 2/6/2010.
132. “Overview of UC Davis Stem Cell Program”. Presented to visiting delegates from Great Britain, UC Davis Medical Center, 02/10/2010.
133. Keynote Speaker, “Huntington’s diseases- possibilities for stem cell therapy”, 7th Annual Huntington’s disease Research Symposium, UCSF, San Francisco, CA 2/20/2010.
17 134. “Human stem cells, from research to therapy”. Presented to the Renaissance Society for active Seniors, Sacramento State University, CA, 02/21/2010.
135. “Overview of the UC Davis Stem Cell Program: Opportunities for International Collaboration.” CIRM – BMBF Germany Networking Workshop, Hyatt Regency Embarcadero San Francisco, CA, March 6, 2010.
136. Public Address at the Grand Opening Event for the Institute for Regenerative Cures, Sacramento CA, March 10, 2010.
137. “Spotlight on Huntington’s disease”. Presented and webcast prior to the meeting of the ICOC – governing body of the California Institute for Regenerative Medicine, Sacramento, CA 03-11-2010.
138. “The importance of assuring genomic stability in Stem Cell Research and Clinical Trials”. Presented at the Pacific Southwest Regional Genetics Seminar. Sacramento, CA 03/13/2010.
Research Support Research Projects - Active:
1) 1RO1 HL073256-01 (Nolta) NIH NHLBI 04/01/03 - 03/31/11 $250,000 DC/yr 2.4 months Effort Functional Dissection of human adipose-derived MSC and bone marrow-derived MSC phenotypes. The goal is to identify the most primitive subsets of primary human MSC and to determine the functional differentiative potential of each defined subset and the homing and tissue regenerative potential in immune deficient mice.
2) TR1-01257: (Nolta) CIRM 08/01/09-07/31/12 $2,753,559 total 3.0 months Effort Sustained siRNA production from human MSC to treat Huntington’s Disease and other neurodegenerative disorders. The goal is to develop a novel MSC-based strategy for stem cell therapy to treat Huntington's disease, leading toward clinical trials.
3) 2RO1DK61848 (Nolta), NIH NIDDK 09/30/01 – 06/30/11 $250,000 DC/ yr. 2.4 months Effort Immunodeficient mouse model of stem cell plasticity. The goal of the proposed studies is to develop immune deficient mouse models in which the origin of blood and liver cells can be traced to a common stem cell precursor and can be rigorously demonstrated by the single cell clonal integration analysis techniques developed in the Nolta lab. Competitive renewal submitted.
4) ARRA Challenge grant (Hagerman PI, Nolta, Pesseh co-Is). 10/2009 -09/2011 $999,924.00 1.2 months Effort Human iPSC neuronal models for FXTAS neurodegeneration The goal of the study is to generate induced pluripotent stem cells from the fibroblast cell lines from the consented FXTAS patients seen by the Hagermans and to study the potential signaling deficits from neurons derived from each pluripotent cell line, in comparison to unaffected controls.
5) CIRM TB1-01184: (Trainer, Jill PI, Nolta Co-PI) 10/01/09 – 09/31/12 Subcontract 0.6 months Effort Bridges to Stem Cell Research Training Program. Bridges is an innovative California Institute for Regenerative Medicine-funded collaborative program between California State University Sacramento (CSUS) and UC Davis to train state college Master’s Program interns in the practical aspects of stem cell biology, good manufacturing practices, good laboratory practices, and Cellular therapy. Subcontract amount varies with student # trained in the UC Davis Stem Cell Program each year.
18 6) 14) CIRM RB2-01567 (Kurzrock PI, Nolta co-PI) $ 441,360/yr DC 2010-2013 0.6 months effort Differentiation of Human Embryonic Stem Cells into Urothelium. Develop methods to derive bladder tissues from embryonic stem cells
7) CIRM RN1-00561 (Chong Pan PI, Nolta Co-mentor) 2008-2013 $300,000 DC/yr 0.6 months effort Combinatorial Chemistry Approaches to Develop Ligands against Leukemia Stem Cells. Dr. Nolta is the stem cell mentor for Dr. Pan’s junior faculty grant, along with Dr. Kit Lam for the chemistry portion.
8) NIH 1R21AR057515-01 (Wei Yao PI, Nolta and Lane, mentors) 2009 – 2012 $275,000 0.6 months Effort Targeting bone homing of the MSCs to augment bone formation. With Dr. Lane, Dr. Nolta serves as a mentor for physician-scientist Dr. Wei Yao. The current application will examine signaling pathways in contribution to osteoporosis. Dr. Nolta's team will assist with siRNA and transduction technologies.
9) ARRA NIH R21 (Kurzrock PI, Nolta Co-I/mentor) 08/2009 – 07/2011 $275,000 0.6 months effort Identification, characterization and enrichment of adult urothelial stem cells. Dr. Nolta serves as the stem cell expert/mentor for Dr. Kurzrock’s NIH grant just funded under the ARRA mechanism. The goal is bladder repair.
10) 1S10RR026825-01 (Nolta) NIH NCRR 01/26/10 $499,785 Shared LSRII Cytometer Equipment Application – this award will fund a shared cytometer for the Stem Cell Program’s Sorter Core in the new Institute for Regenerative Cures.
11) CIRM RFA0903 (Murphy PI, Nolta co-PI) $154,807/yr 2010-2013 1.8 months effort Natural killer (NK) cells as “veto” cells to promote donor-specific tolerance Develop methods to tolerize recipients to engrafted tissues by the use of donor NK cells
Pending- Submitted grants currently under review (July 2010)
12) NIH NIDDK R01 (Nolta PI) 2011-2014 250,000 DC/yr 2.4 mo. Effort Liver repair using decellularized matrix and iPSC derivatives The goal is to continue to test liver neo-organoid creation and implantation into immune deficient mice as a method for liver repair for patients who are not eligible for a liver transplant.
13) UCD Center for AIDS Research (Dandekar PI, Pollard/Nolta Core Leaders) 2011- 2014 0.6 months effort Clinical and Translational Research Core (CTRC) The goal of the core is to provide humanized mouse models and translational oversight for CFAR members
14) 8113124; PAR10-199 - NINDS Exploratory Clinical Trials (R01) 499,000 DC/yr 1.2 mo. Effort Neurorestorative MSC Therapy for Huntington's disease The goal of the proposal is to perform a phase 1 clinical trial of human mesenchymal stem cell (MSC) implantation into the striatum to treat Huntington’s disease (HD). We will explore the safety as well as preliminary efficacy of this procedure by measuring clinical measures of motor, cognitive, and psychiatric function as well as volumetric MRI measures of striatal, cortical and white matter volume at baseline and 6 months after implantation in a cohort of 15 patients with Huntington’s disease.
Previous Grants 15) CIRM FA-00611-1: Institutional grant: Nolta, designated contact, $20,083,000 CIRM Major Facilities Grant: this award was for “Bricks and Mortar” and equipment for renovation of the new
19 UC Davis/CIRM Institute for Regenerative Cures, which will house the rapidly growing UC Davis stem cell program (currently 145 faculty members).
16) 5P30AG010129 - 19 (DeCarli, PI, Nolta - Pilot grant PI) 10/09-09/10 $34,000 The goal of this pilot project on Dr. DeCarli’s center grant is for Dr. Nolta to mentor Dr. Olson in her lab, who will investigate the use of human MSC to deliver biotherapeutics for Alzheimer’s disease directly into the brain tissue.
17) 1R01HL073762-01 (Link), NIH NHLBI 07/01/03 – 06/30/07 $250,000 DC/yr Stem Cell Mobilization to enhance tissue repair. Regimens to mobilize murine hematopoietic, mesenchymal, and endothelial progenitors capable of mediating repair of damaged cardiac tissue were determined.
18) 2R01DK53041 (Nolta), NIH NIDDK 09/30/97 - 04/30/07 $250,000 DC/yr Ex-vivo Stem Cell Manipulation and Human Hematopoiesis. The goal was to promote primitive human hematopoietic progenitor survival and self-renewal in vitro, and to determine molecular changes that precede lineage commitment in human stem cells.
19) HL54850-02 (Nolta), NIH NHLBI 1/1/01 - 12/31/06 $242,000 DC/yr Specialized Center of Research (Parkman), Project 2 (Nolta); In vivo model for human stem cells. The goal of this project was to examine transduction, in vivo differentiation, and the molecular aspects of cell cycle regulation in human hematopoietic stem cells.
20) 1R21DK62892-01 (Nolta) NIH NIDDK 03/01/03 – 02/28/06 $100,000 DC/ yr. HGF (Hepatocyte growth factor) induces robust human thymopoiesis in mice The goal was to produce better xenograft models in which to examine human T cell reactivity. The models are now used by the UC Davis HIV team researchers.
20 TEACHING TITLE AND RESPONSIBILITIES:
Teaching prior to UC Davis
Organizing and lecturing (6 lectures) MICB 502; Advanced Immunology Class for Graduate students, University of Southern California Department of Microbiology, Fall 2001. Changed format from two one hour lectures per week to a one hour lecture by guest speaker, followed by a one hour journal club on a relevant current paper, presented by Dr. Nolta or a postdoctoral fellow volunteer. This format was felt to keep the lectures more relevant and the topics more current.
Oncology Student Seminar series, Washington University School of Medicine in St. Louis. Taught gene therapy techniques and clinical applications, October - November, 2002.
Hematology 101; course for medical fellows at USC: Presented 2 lectures on Stem Cell Plasticity, February 2002.
"Immune Deficient Mouse interactive Workshop" Seminar series presented at USC School of Medicine, January 17, February 7, February 28, 2002.
High School Mentoring Program: Marlboro High, Littlerock High, Marshall High, 1998-01.
Marlboro High School Laboratory Training Program, 1999 - 2000.
Directed Student Journal Club, Childrens Hospital Research Institute 1997 - 1998. “New advances in hematopoietic stem cell biology”. Assigned papers and headed weekly discussion.
Gene Therapy Seminar Series: Biochemistry Department, Littlerock High School, Littlerock, CA. May 1998, April 1999.
Headed Laboratory Journal club, Childrens Hospital Los Angeles, 1998-2002. Topic: Student’s choice of papers pertaining to transplantation of stem cells into mice.
Participation in Signal transduction Journal club, Childrens Hospital Los Angeles, 1998-2002. Topic: Choice of the PI or Postdoctoral fellow. Roundtable discussion. Twice a month.
Participation in discussion at each weekly seminar or graduate student chalk talk sponsored by the CHLA Research Institute. 1990-2002.
Presented review sessions for the Division of Research Immunology/ BMT and other CHLA RI faculty, after each international and national meeting attended, 1995-2002.
Different Stem Cell Sources for Tissue Repair. Syllabus preparation plus 2 hours lecturing for Biology course, Missouri State University, Springfield, MO, October 7th, 2005.
Stem Cells in Cancer Development and tissue repair. Taught Short Course in Cancer Biology at the University of Nebraska Medical Center, Omaha, NB. 4 hours lecturing. Advance Syllabus preparation. May 8-9, 2006.
21 Embryonic vs adult human stem cells in tissue repair. Two hour lecture presented to the Tissue Engineering class organized by Hari Reddi, UC Davis, February 26, 2007.
Hematopoiesis 101: the History of Hematopoietic Stem Cell Research. 2-hour lecture for scholars of the California Institute for Regenerative Medicine. Class organized by Alice Tarantal, UC Davis. 4/13/07
Laboratory meeting each Monday, 9:30 AM – 11 AM, followed by Journal club, 11 AM-noon. For members of the Nolta laboratory plus any interested members of the Division of Research Immunology, CHLA, and rotating students/ trainees 1997-2002. Continued at Washington University, 2002-2007, and at UC Davis, 2007-present.
2002 – present: Individual mentoring of Graduate students, Postdoctoral fellows, Summer students, Volunteers, high school students. Minimum of one hour per week in individual plenary meetings with each student, plus laboratory training/ supervision for lab members and other students in the division as needed, on a daily basis.
Students Former and current students are listed below, with their accomplishments.
Former students
David Hess, Postdoctoral fellow, 2003-June 2006. Multiple abstracts, two oral presentations at the American Society of Hematology Conferences, 2003, 2004. Multiple poster presentations. Two first author papers in Blood. Three manuscripts in preparation, two others submitted from the Nolta lab. Obtained $350,000/year in his own funding and was promoted to Instructor at Washington University, 2005. Obtained an Assistant Professor position at the Robarts Institute in London, Ontario, July 2006.
Jesper Bonde, Postdoctoral fellow, 2003-2005. Multiple abstracts, oral presentation at the Conference on Gene Therapy and in Vivo Imaging, Sonoma, CA, November 2004. Poster presentation at the American Society of Hematology conference, 2004. One first author MS, One second author, two other papers in revision. Obtained a faculty position in Denmark, Dec. 2005.
Todd Meyerrose Graduate student, USC school of Medicine, August 2000 – 2002. Relocated with the Nolta lab. Washington University 2002-2006. Multiple abstracts, one first author manuscript in Stem Cells, 2006 and another two in preparation. Multiple collaborative papers while in Nolta lab. Presented data at the American Society of Hematology Meeting, December 2000, and in the Presidential symposium at the International Society of Experimental Hematology in Montreal, 2002, and the non- hematopoietic stem cell conference in New Orleans, 2003. Completed thesis dissertation at Washington University 2007, obtained a postdoctoral position with Dr. Rudy Jaenisch, Whitehead Institute 2007.
Mo A. Dao, Graduate student, USC School of Medicine. 1996 - 2001. Ph.D. June 2001: “Manipulation of intracellular and extracellular factors controlling the fate of primary human hematopoietic progenitors – a molecular approach toward gene therapy.” Received the graduate student merit award from the American Society for Hematology for the highest scoring abstract submitted by a graduate student for the 1998 Meeting (15,000 scientists attending). Numerous other symposia, invited chapters, and abstracts. Presented data at National Meetings each year. Accepted for postdoctoral training in the laboratory of Catherine Verfaillie, July 1, 2001-Nov. 2004. Returned to Nolta lab for a second postdoc, November 2004-. Sixteen first author papers from the Nolta Lab, listed
22 in Pubmed, plus four second author contributions, and one middle author. Senior scientist, Sanbio, inc, Palo Alto CA
Taylor Cordonnier-High School Summer student, 2002, 2003. Worked on stem cell plasticity projects, with transplantation of human MSC in immune deficient mice, summers of 2002, 2003. His work was a part of a paper published in Stem Cells, and was featured in an abstract presented at the 2002 meeting of the American Society of Hematology. Accepted to Washington University, Fall 2004.
Timothy Craft, pre-med student 2003 – 2005. Developed techniques to study liver regeneration in NOD/SCID/MPSVII mice. Four second author papers resulted from his work on stem cell plasticity. Accepted to Emory University School of Medicine for fall semester 2005.
Eleanor Tsark, Post-Doctoral fellow, CHLA, 1998-99. First author publication in Journal of Immunology, 2000. Three other publications, numerous abstracts. Presented data at National Scientific Meetings. Obtained an instructor position at the City of Hope Medical Center, Department of Immunology.
Xiuli Wang, Postdoctoral fellow (Research Scholar), CHLA, July 1999 - 2002. One first author paper, plus a second author publication in Journal of Immunology, 2000. An additional first author paper published in Blood, 2004, resulting form her primary project in the Nolta lab. Numerous abstracts. Presented data at National Scientific Meetings. Obtained a position with the Department of Bone Marrow Transplantation at Childrens Hospital of Los Angeles, May 2002.
Tae-Ho Kim, M. D. Fellow (laboratory mentorship), CHLA, Dec. 1999-2002. Four abstracts, one manuscript in preparation. Obtained a training grant application to the NIH based on collaborative work with the Nolta lab.
Joseph Hwa, Summer student (high school), Childrens Hospital of LA, 2000-2002. Two abstracts, one second author manuscript from his work in the Nolta lab, published in Blood. Currently in the Bioengineering program at Cal-Tech, Pasadena, CA.
Erin Zomber, Student volunteer from Marlboro High School, 1999 - 2000. One abstract. Now enrolled at the University of California, Santa Barbara.
Janice Arakawa-Hoyt, Masters student, University of Southern California, 1997-1999. One first author manuscript in Bone Marrow Transplantation. Two other papers and several abstracts. Presented data at National Scientific Meetings. Currently continuing her studies in the laboratory of Y. W. Kan, University of California, San Francisco.
Isabel Kuo, Summer student (high school), Childrens Hospital of LA, June-August 2000. One Publication, 2 abstracts. Returned to Nolta lab Summer 2001, and obtained a 2nd author paper from that work. Currently in Medical School at St. Louis University.
Susie Wells (Medical Technician trainee) Obtained one first author paper, two other papers, and four abstracts while in the Nolta lab. Attended two national meetings. Continued training in Don Kohn’s lab, performing clinical gene therapy trials. Running QC program at the City of Hope Hospital, Duarte CA.
Azim Mohammedali (Postdoctoral Fellow), Childrens Hospital of Los Angeles and USC school of
23 Medicine, 2000-2002. Gene Therapy Scholar program. Three abstracts presented at national meetings, one first author manuscript. Continued his postdoctoral studies with Dr. NSB Thomas, in London England.
Manoj Rao: Medical Fellow, Summer student in the Nolta laboratory at Washington University. Worked on stem cell plasticity projects, with histology, sectioning, and immunohistochemical staining of human cells in immune deficient mice, summer of 2002. Currently in Medical School, St. Louis University.
Ivana Rosova, Graduate student, 2002-2008. Several abstracts, participated in obtaining data for three MSC book chapter, and had one first author paper published in Stem Cells, another submitted 2009, one second author paper, and several participating author papers published, in revision and in preparation. Completed thesis in 2008, was housed in collaborator Dan Link’s lab at Washington University, after the Nolta lab move Feb. 2007.
Ryan Lahey, Summer student, excelled in the lab and then continued as a part-time technician while attending Washington University undergraduate program in Bioengineering, June 2004 - 2007. Two abstracts, co-author on three manuscripts in preparation, and one paper in press in “Stem Cells”. Relocated to UC Davis with the Nolta lab 2007, accepted to MD/PHD program in Champagne, Urbana, fall 2008.
Current Students
Ping Zhou, Postdoctoral fellow, 2005-present. Dr. Zhou relocated to UC Davis with the Nolta lab. She is working on our plasticity grant projects, designing experiments for stem cell-mediated liver repair, and overseeing the technicians who work on this grant. She has had twenty manuscripts published (ten with the Nolta lab), numerous abstracts and two new papers in preparation. She presented a well- received platform session at the annual Meeting of the American Society of Hematology in Atlanta, December 10, 2007. Promotion to Faculty Project Scientist pending, 2010.
Suzanne Pontow, Ph.D. Instructor, 2005-2007, SRA V, May 2007-present, after relocating to UC Davis with the Nolta lab. Dr. Pontow is running Dr. Nolta’s gene therapy grant projects, designing experiments for stem cell transduction, and overseeing the technicians who work on this grant. She has 12 papers, several abstracts and a new paper on stem cell isolation from placenta and wharton’s jelly in preparation. She is expert at stem cell isolation and running clinical trials in the GMP facility. Promotion to Faculty Project Scientist pending, 2010.
Claus Svane Sondergaard, PhD: Outstanding graduate student from Denmark who joined the Nolta lab for a 6 month training program, 2005 – 2006. Dr. Sondergaard relocated from Denmark to join the lab for his second postdoctoral position, April 2009-present, focusing on cardiac repair by human stem cells in xenograft models. Dr. Sondergaard is currently working on vascular regeneration in peripheral vascular disease (with Dr. Fierro), tissue engineering of cardiac tissue (with Dr. Si) and is assisting with various other projects including characterizing wound repair by embryonic and neonatal stem cells. Dr. Sondergaard has four published peer review publications and numerous abstracts. Since joining the Nolta lab, Dr. Sondergaard has one accepted paper in press and one submitted paper pending revision, both as first author plus two manuscripts in preparation as co-author - he presented a poster at the 50 th annual meeting of the American Society of Hematology in New Orleans in December of 2009.Dr. Sondergaard has previously been awarded grants and stipends by among others the Danish Stem Cells
24 Doctoral School, the Danish Heart Association and the Danish Cancer Association.
Whitney Cary, Undergraduate, 2009-present. Whitney Cary is a third year U.C. Berkeley undergraduate majoring in Molecular and Cellular Biology-Neurobiology Emphasis. She works Friday through Sunday in the Nolta Lab Stem Cell Core deriving neurons from embryonic stem cells to create an in vitro model of HD for Huntington's disease research. She has presented three oral seminars on her current work at community events and will be an author on a paper in preparation. She will apply to the graduate program at UC Davis in 2011.
Matt Lindsey, Rockville High School Student, 2005 – 2007, CSUS student 2007 - 2010. Matt learned GMP manufacturing procedures in the cell processing facility at Washington University, under Dr. Nolta and Bauer’s direction. Made retroviral vector supernatants and set up SOPs for titering and RCL activity. He continued through the semester as part of an outreach program and was elected “high school student of the year” in Missouri, March 2006, partially due to his outstanding scientific achievements. He relocated to UCD with the Nolta lab in 2007 and is currently taking classes toward a degree in nursing at California State University, Sacramento, while working in the Nolta lab vector core. He has 5 abstracts and a manuscript in preparation.
Yunjoon Jung, International Graduate Student, 2008-present. Yunjoon is working on our induced pluripotent stem (iPS) cell grant projects (FXTAS, Huntington's disease, and Amyotrophic lateral sclerosis), designing experiments for disease specific iPS cell generation. He has one manuscript published, and three papers in preparation. He is in the Department of Biomedical Engineering and was awarded a Howard Hughes Medical Institute scholarship for his graduate work.
Scott Olson, Ph.D., Postdoctoral Fellow, 2007-present. Dr. Olson works with adult mesenchymal stem cells (MSCs) studying their potential for use in treating some neurological diseases, such as Huntington's and Alzheimer's, as well as consulting on the usage of MSCs in a number of other applications. Dr. Olson oversees the microscopic instruments of the lab, conducting short-term and long- term time-lapse microscopy of live cells. He has published 8 papers, has one in submission, and two in preparation, and has published abstracts presented at ISSCR, ISCT, and the International Conference on Mesenchymal and Non-Hematopoietic Stem Cells.
Astra I. Chang, International Graduate Student from Canada, 2008-present. Graduate Group in Comparative Pathology. Astra is working on our cancer stem cell team, designing and conducting experiments to identify and target tumor initiating and metastasizing cancer stem cells. She was an Inaugural Howard Hughes Medica Institute IMBS Scholar at UC Davis and has had two manuscripts, one abstract, and two reports published, with one manuscript pending with her previous lab where she completed her M.S. in Cellular and Molecular Medicine.
Gaela-Marie Mitchell, Post Baccalaureate junior specialist. January 2010 - present. Ms. Mitchell graduated from the University of California at Davis with a B.S. in Biological Sciences, Medical Microbiology emphasis. While volunteering in the Nolta lab during 2009, she successfully generated Medium Spiny Neurons for use in Huntington's disease research. She presented to the Huntington's disease Society of America - Northern California Chapter on January 30, 2010, and has a manuscript in preparation. In addition to her HD work, she assists on projects for the Embryonic Stem Cell Core in the Nolta Lab.
John Javien, Medical student, UCD, spent one year (2008-2009) in the Nolta/Bauer lab doing HIV-
25 related research. Was awarded best poster at the Medical student poster show, 2009.
Joseph Anderson, Ph.D., Postdoctoral Fellow, co-mentored with Gerhard Bauer. Numerous abstracts, two first-author papers with the Nolta/Bauer labs. Promoted to faculty May 1 2010.
Jing Liu Ph.D., Postdoctoral fellow, 2006-present. Dr. Liu joined Nolta lab in 2008 funded by Shriners Hospital Fellowship. She is working on dopaminergic neuron differentiation from human embryonic stem cells and induced pluripotent stem cells for microRNA profiling. She has had fourteen manuscripts published and numerous abstracts.
Stefanos Kalomoiris, international junior specialist from Greece
Fernando Fierro, Ph. D., Postdoctoral Fellow
Claus Sondergaard, Ph.D., Postdoctoral Fellow, co-mentored with Ming Si, Dept. cardiac surgery
Jon Walker, CSUS student - undergraduate
Elena Nedelcu, MD, Medical Fellow, apheresis unit, mentored under MCRTP program
Benjamin Lin- Medical student, co-mentored with Rivkah Isseroff, funded by CTSC training grant
Tun Nyunt, graduate student, co-mentored with CBST
Students: Short-Term Training – Laboratory:
Stefan Verlinden, Ph.D.: Student sent from Dr. Dirk Von Bekkum’s laboratory, the Netherlands. Trained for one month in the Nolta lab to learn gene transfer techniques.
Amit Sanyal, Ph.D.: Student sent from Dr. Friedrick Scheuning’s lab, Fred Hutchinson Cancer Center, Seattle, WA. Trained for 1 month in the Nolta lab to learn xenotransplantation.
Jesusa Arevalo, Punam Malik, MD: Were taught hematopoietic stem cell Laboratory techniques by Dr. Nolta (3-6 month course) when they first arrived at Childrens Hospital of Los Angeles.
Jason Brandt and Kathy Partlow from collaborator Samuel Wickline’s laboratory- were taught cell sorting and culture methods by Todd Meyerrose and Dr. Nolta, at Washington University. 2007
Drew Hope: Medical fellow who worked temporarily in the Nolta lab, to learn in vivo tissue repair strategies for lung damage. 2007
Ph.D. Thesis committees:
Monique Dao, University of Southern California
26 A. Alex Hofling, Washington University Todd Meyerrose, Washington University Jay Dritz, Washington University Hilary Luderer, Washington University Kathy Partlow, Washington University Anthony Donsante, Washington University Ivana Rosova, Washington University Megan Griffey, Washington University Kyle Eash, Washington University Claus Sondergaard, Aarhus University, Denmark Mary Saunders, UC Davis Marni Morales, UC Davis Padmini Sirish, UC Davis Jennifer Johns, UC Davis Ambrose Williams, UC Davis
Teaching: Courses taught and Student Seminars Presented at Places of Employment: CHLA/ USC School of Medicine, Washington University School of Medicine, and University of California at Davis:
1. Long-term bone marrow culture and the CFU-GEMM assay: Research and clinical applications. Presented to the Division of Rheumatology, Childrens Hospital of Los Angeles, February 1990.
2. Bone marrow culture models for the study of gene transfer. Presented at Hematology/Oncology Grand Rounds, CHLA , Los Angeles, CA, March 1990.
3. A xenograft model for human gene therapy. Presented to the Division of Microbiology, University of Southern California School of Medicine, Los Angeles, CA, Nov. 1992.
4. Gene therapy and bone marrow transplantation. Presented to the Department of Neurology, USC School of Medicine, March, 1993.
5. In vivo model of human bone marrow gene therapy. Presented at the Los Angeles Bone Marrow Transplant Annual Meeting, May 1993.
6. An immunodeficient mouse model for human gene therapy. Presented at the Biology Research Symposium, University of Southern California, March, 1993.
7. Analysis of retroviral-mediated transduction of primitive human hematopoietic progenitors. Presented to the Division of Hematology/Oncology, Univ. Southern California, Feb. 1994.
8. In vivo model for analysis of retroviral-mediated transduction of primitive human hematopoietic progenitors. Presented to the Faculty of the Graduate School, University of Southern California, Los Angeles, CA, May 1994.
9. A Xenograft System to measure levels of retroviral transduction and the impact of ex-vivo culture on primitive human hematopoietic stem cells. Gene Therapy Meeting, Childrens Hospital of Los Angeles, September 1997.
27 10. Human B Lymphocyte development in immunodeficient mouse xenograft models. Presented to the Division of Bone Marrow Transplantation, CHLA, Sept. 1997.
11. Cell cycle manipulation in primary human hematopoietic stem cells. Presented to the Division of Research Immunology, weekly seminar series. November 1998.
12. Progress toward optimization of retroviral - vector mediated gene transfer techniques. University of California, Los Angeles Symposium on Gene Therapy, June 14, 1999.
13. Extrathymic human T lymphocyte development in nude mice. Presented to the CHLA Research Institute, weekly seminar series. November 1999.
14. In vivo models for assaying stem cell function. Stem Cell Transplantation and Gene Therapy Symposium, Department of Pathology and Laboratory Medicine, USC/ Childrens Hospital Los Angeles. October 16, 1999.
15. Hematopoietic stem cells: What’s new? USC Developmental Biology Program Scientific Retreat, Descanso Gardens, La Canada, CA, May 17, 2000.
16. Stem cell research is changing: International Society of Hematology 2000 update. Presented to graduate students, technicians at CHLA, July 24, 2000.
17. Gene Therapy Program: Progress and Update 1996 – 2000. Presented at the Faculty Retreat and External Review, Hilton Hotel, Glendale, California November 18, 2000.
18. Review of the 2000 meeting of the American Society of Hematology: new advances in gene therapy and stem cell plasticity. Presented to the faculty and students at CHLA Research Inst., Dec. 8, 2000.
19. Stem Cell Plasticity: Literature Review followed by a roundtable discussion. Presented at the CHLA Research Institute, weekly seminar series. February 8, 2001.
20. Hematopoietic Stem Cells: Looking Beyond Dogma. Presented for Hematology/ Oncology Grand Rounds, University of Southern California, February 21, 2001
21. Mouse xenograft models to study human hematopoietic stem cell biology and gene therapy. Presented to the Department of Oncology, Washington School of Medicine, St. Louis, MO, April 24, 2001.
22. The use of immune deficient mice and clonal integration marking to study human stem cell plasticity. Presented at the weekly conference series for the USC Center for Liver Disease , September 20, 2001.
23. Murine xenograft models to study human hematopoietic, mesenchymal, and "plastic" stem cells. Presented at the CHLA Research Institute, weekly seminar series. Feb. 5, 2002.
24. Immune deficient mice: strategic planning session. Presented with Phillip Herrbrich at the Research Immunology Seminar Series, CHLA, February 28, 2002.
28 25. Retroviral transduction and Mesenchymal Stem Cells for systemic protein delivery. Presented to the Stem Cell Biology Section at Washington University school of Medicine, May 1, 2002.
26. Immune Deficient Mouse Models For Human Hematopoietic and Mesenchymal Stem Cell Plasticity Research. Presented to the Washington University Stem Cell plasticity group on May 16, 2002.
27. The Ethics of Stem Cell Research. Seminar given to the members of the St. Louis Academy of Science in St. Louis on May 23, 2002.
28. Hematopoietic Stem Cell Gene Therapy: what have we learned over the past decade? Presented at Medical Grand Rounds, Washington University School of Medicine, September 5, 2002.
29. Update from the second annual Mesenchymal and Non-Hematopoietic Stem Cell Meeting in New Orleans. Presented to the Washington University Stem Cell Plasticity Group on October 3, 2002.
30. Hematopoietic Stem Cell Gene Therapy: what have we learned over the past decade? Presented at Medical Grand Rounds, Washington University School of Medicine, September 5, 2002.
31. Immune deficient mouse model of human hematopoietic to hepatic stem cell plasticity. Presented to the Department of Gastrointestinal Medicine, Washington University School of Medicine, February 7th, 2003.
32. Progress Toward Optimizing Immune Deficient Mouse Models for Human Hematopoietic and Mesenchymal Stem Cell Homing and Plasticity. Presented at Medical Grand Rounds, Washington University School of Medicine, March 2003.
33. Mesenchymal stem cells. Presented to the Department of Orthopedic Surgery, Washington University School of Medicine, February 2004.
34. Stem cell plasticity- Hype or hope? Presented at Hematology Grand Rounds, Washington University School of Medicine, May 2004.
35. Novel cell sorting and transduction methods, studied in immune deficient mouse xenograft models. Presented at Grand Rounds, University of Southern California at Davis, June 2004.
36. Umbilical cord blood stem cells: working toward clinical models of tissue repair and cellular therapies. Presented at St. Louis University, Department of Oncology, November 10, 2004.
37. The roles of SDF-1 and hepatocyte growth factor in tissue injury and repair. Presented to the Stem Cell Group at Washington University, Jan. 4, 2005.
38. Review of the field of human tissue repair. Presented to the Medical Fellows in the Oncology Lecture series, Washington University School of Medicine, Feb. 8. 2005.
39. Lecture and roundtable discussion on adult vs. embryonic stem cell plasticity (co-hosted with Dr. Teitlebaum). Presented at the Washington University Molecular Biology Graduate student retreat, October 2005.
29 40. Mesenchymal stem cells, the cellular paramedics. Presented to the Department of Orthopedic Surgery, Washington University School of Medicine, January 2006.
41. Umbilical cord blood-derived stem cells for cardiac, liver, and pancreas repair. Presented at Grand Rounds, Saint Louis University School of Medicine, Department of Oncology, Jan. 2, 2006.
42. Mechanisms governing human stem cell homing to areas of hypoxia in damaged tissues. Presented at Oncology Grand Rounds, Washington University, Feb. 10, 2006
43. Immunodeficient mouse models to examine the effects of hypoxia on adult stem cell homing in tissue repair. Hematology grand rounds, Washington University, Feb 10, 2006.
Courses taught: UC Davis 2007 – present
44. 2007 UC Davis Winter Quarter 272 Tissue Engineering
45. 2008 UC Davis Winter Quarter BMB 290 Medical Applications of StemCell Technology
46. UC Davis Winter Quarter 294 MCB/ECH, 2008
47. 2008 Spring Quarter BIO 186A Stem Cell Technology and Medical Applications
48. 2008 Seminar in Cellular and Molecular Biology, CSUS, Dept. of Biological Sciences.
49. 2008 Spring Quarter HON 493 Cancer as a Process Special Study Module for 4th Year Medical Students, UC Davis, Sacramento, CA
50. 2008 UC Davis Fall Quarter CLH 250 Integrating medicine into basic science
51. 2009 Hematology Journal club for medical students
52. 2007 Winter Quarter Lecture: Embryonic vs. Adult Human Stem Cells in Tissue Repair, 271 Tissue Engineering Class, UC Davis, Davis CA (organized by Dr. Hari Reddi)
53. 2007 Spring Quarter Lecture: Hematopoiesis 101: The History of Hematopoietic Stem Cell Research, Scholars of the California Institute for Regenerative Medicine (organized by Dr. Alice Tarantal). University Of California, Davis. Davis, CA
54. 2007 Spring Quarter Lecture: Stem Cell Therapy, Hem Onc Journal Club, UC Davis Cancer Center, Sacramento, CA.
55. 2007 Summer Special Session Lecture: Human Stem Cell Sorting, UC Davis Biotechnology Program short course on Flow Cytometry. University Of California, Davis, CA.
56. 2007 Summer Special Session Lecture: Human Stem Cells for Tissue Repair, Howard Hughes Medical Students, UC Davis Genomics Building, Davis CA
30 57. 2008 Winter Quarter Lecture: Embryonic vs. Adult Human Stem Cells in Tissue Repair, 271 -Tissue Engineering Course, (organized by Dr. Hari Reddi - IOR). University Of California, Davis. Davis, CA
58. 2008 Spring Quarter Lecture: The Promise of Stem Cell Therapy, MCB/ECH 294 Current Progress in Biotechnology course, UC Davis Biotechnology Program, Davis, CA
59. 2008 Summer Quarter Lecture: CLH 250: Integrating medicine into basic science
60. 2008 Extra Session Other: 1996 – present: Individual mentoring of Graduate students, Postdoctoral fellows, Summer students, Volunteers, high school students. Minimum of ½ hour per week in individual plenary meetings with each student, plus laboratory training/ supervision for lab members, other students, and junior faculty members in the Stem Cell Program as needed, on a daily basis, Oak Park Research Building, Sacramento, CA. University of California, Davis.
61. 2008 Summer Special Session Lecture: Human Stem cells as Therapeutic Agents, Edmondson Summer Research Internship Program for pre-med and pre-grad students, University Of California, Davis. Davis, CA
62. 2008 Summer Special Session Lecture: Human Stem Cell Sorting. UC Davis Biotechnology Program short course on Flow Cytometry, University Of California, Davis. Davis, CA
63. 2008 Fall Quarter Lecture: Stem cells for revascularization of ischemic tissue. CLH 250: Integrating medicine into basic science (Knowlton, AA IOR), University Of California, Davis, CA
64. Stem Cells 101, “Stem Cells in the Study and Treatment of Neurodegenerative Diseases”, Presentation, UC Davis, Bridges CIRM Stem Cell Program, Sacramento, CA 07/09/2009.
65. Stem Cell Biology and Regenerative Medicine, “Adult Stem Cells and Angiogenic Therapies”, Lecture/Class, Summer School for T32 Program in Basic and Translational cardiovascular Science, UC Davis, Davis, CA 07/21/2009.
66. “Stem cell migration and homing to repair tissue injury”. Lecture, Biomedical Engineering graduate Course BIM 272, 02/22/2010.
Teaching: Student seminars taught at UC Davis 2007 – present
67. Stem cells for tissue repair. Presented at UC Davis School of Medicine, April 13, 2006.
68. Human stem cells for tissue repair: state of the art. Presented at the 4th annual retreat, UC Davis Center for Biophotonics Science and Technology, Squaw Valley, CA, July 12, 2006.
69. Embryonic vs adult human stem cells in tissue repair. Two hour lecture presented to the Tissue Engineering class organized by Hari Reddi, UC Davis, February 26, 2007.
70. Immune deficient mouse models of soft tissue repair. Presented at the noon conference, Shriner’s Hospital, Sacramento CA. March 26, 2007.
31 71. Adult vs embryonic stem cells; working toward effective strategies for tissue repair. Presented on May 4, keynote speaker at the UC Davis Pathology Retreat, Lake Tahoe, 2007.
72. The UC Davis Stem Cell Program: working toward tissue repair. Presented at the UC Davis Cancer Center retreat at Squaw Valley, June 17-19, 2007.
73. Human Stem Cell Sorting. One hour lecture presented in the UC Davis Biotechnology Program short course on Flow Cytometry, July 19th, 2007.
74. Immune deficient mouse models to study human stem cell biology. Presented at the UC Davis Center for Comparative Medicine noon Seminar, July 24, 2007.
75. Human stem cells for tissue repair. Howard Hughes Medical Student Lecture. UC Davis Genomics Building, 1-3 PM, August 16, 2007.
76. Mesenchymal stem cells for revascularization and bone repair. Lecture presented to the UC Davis School of Veterinary Medicine, equine group. Vet Med 3, 10-noon, September 5, 2007.
77. The future of Stem Cell Therapies. Lecture to regional students and High School Teachers for UC Davis’ NIH Training Program in Biomolecular Technology. Workshop in the Science Teaching Building, UC Davis, 1-3 PM Saturday, September 9, 2007.
78. Tumor Stem Cells- getting to the root of the malignancy. Cancer Biology Research Seminar, presented to Medical students and members of the UC Davis Cancer Center Basic Sciences Program. 9-10 AM October 11, 2007.
79. Imaging and in vivo tracking of stem cells. Lecture presented to students and faculty at the joint workshop on Biophotonic Applications in Regenerative Medicine. 11AM-noon, UC Davis Medical Center, November 2, 2007.
80. UCD Bioinformatics Fall Workshop #1: Stem Cells to Repair Injured Tissues, 9/29/2007
81. UCDMC: Cancer Biology Research Seminar, 10/11/2007
82. HHMI IMBS Training Program: Human Stem Cells in Regenerative Medicine, 8/16/2007
83. NSF Funded High School Teachers: the promise of stem cell therapies, UC Davis 9/29/2007.
84. BMB 290 course lecture, UC Davis Storer Hall: Medical Applications of Stem Cell Technology, 1/15/2008
85. Veterans Administration Hospital/UC Davis traumatic brain injury workshop: Stem Cells for Tissue Repair, 2/22/2008.
86. UCD Biotechnology Program. Current Progress in Biotechnology: The Promise of Stem Cell Therapy, 4/11/2008.
32 87. BIO 186A: Seminar in Cellular and Molecular Biology, CSUS, Dept. of Biological Sciences. Stem Cell Technology and Medical Applications, 4/15/2008.
88. Cancer as a Process Special Study Module for Fourth Year Medical Students. Stem Cell Therapies: Bench to the Bedside, 5/1/2008.
89. “Cancer Stem Cells and Related Research at UC Davis”, Presentation/Retreat, T32 Oncogenic Signals and Chromosome Biology Retreat, UC Davis, CA, 05/11/2009.
90. UCDMC Pathology Department Grand Rounds: Human Stem Cells for the Repair of Disease and Tissue Injury, 6/2/2008.
91. Edmondson Summer Research Internship Program for pre-med and pre-grad students: human stem cells as therapeutic agents. 6/24/2008
92. Stem Cells 101, “Introduction to Stem Cells”, Lecture/Presentation, UC Davis/CSUS Bridges Program, Stem Cell Program, Sacramento, CA 06/24/2009.
93. BIM 290 (Fall 2009) Student Seminar Series, UC Davis, “Stem Cell Research”, Speaker, Davis, CA 11/2/2009
94. Integrating medicine into Basic Science, “Human Stem Cells to Heal Injury and Disease”, Presentation, Howard Hughes Medical Institute, Sacramento, CA 07/08/2009.
33 BIBLIOGRAPHY
Peer Reviewed Manuscripts
1. Barranger JA, Ohashi T, Hong CM, Tomich J, Aerts JF, Tager JM, Nolta JA, Sender LS, Weiler S, Kohn DB. Molecular pathology and therapy of Gaucher disease. Japanese Journal of Inherited Metabolic Disease 51:45-71, 1989.
2. Nolta JA, Sender LS, Barranger JA, Kohn DB. Expression of human glucocerebrosidase in murine long-term bone marrow cultures following retroviral vector-mediated transfer. Blood 75:787-97, 1990.
3. Ozkaynak MF, Nolta JA, and Parkman R. In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide. Cancer Research. 50:1455-1458, 1990.
4. Nolta JA, Kohn DB. Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative status of human hematopoietic progenitor cells. Human Gene Therapy 1:257-268, 1990.
5. Lenarsky C, Weinberg K, Petersen J, Nolta J, Brooks J, Annett G, Kohn D, and Parkman R. Autologous bone marrow transplantation with 4-hydroperoxy-cyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission. Bone Marrow Transplantation 6:425-429, 1990.
6. Kohn D, Nolta J, Weinthal J, Bahner I, Yu X-J, Lilley J, and Crooks G. Towards gene therapy for Gaucher disease. Human Gene Therapy 2:101-105, 1991.
7. Weinthal J, Nolta JA, Yu XJ, Lilley J, Uribe L, and Kohn DB. Expression of human glucocerebrosidase following retroviral vector-mediated transduction of murine hematopoietic stem cells. Bone Marrow Transplantation 8:403-412, 1991.
8. Tishler DM, Weinberg KI, Sender LS, Nolta JA, and Raffel C. Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system. Journal of Neurosurgery 76:507-512, 1992.
9. Nolta JA, Yu XJ, Bahner I, and Kohn DB. Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow. Journal of Clinical Investigation 90:342-348, 1992.
10. Nolta JA, Crooks G, Overell R, Williams D, and Kohn D. Retroviral vector-mediated gene transfer into primitive human hematopoietic progenitor cells: effects of mast cell growth factor (MGF) combined with other cytokines. Expt. Hematology 20:1065-1071, 1992.
11. Nolta JA, Hanley ME, and Kohn, DB. Sustained human hematopoiesis in immunodeficient mice by co-transplantation of marrow stroma expressing human I L-3: analysis of gene transduction of long- lived progenitors. Blood 83: 3041-3051, 1994.
12. Hanley ME, Nolta JA, Parkman R, and Kohn DB. Umbilical cord blood cell transduction by
34 retroviral vectors: preclinical studies to optimize gene transfer. Blood Cells 20: 539-546, 1994.
13. Nolta JA, Smogorzewska EM, and Kohn, DB. Analysis of optimal conditions for retroviral- mediated transduction of primitive human hematopoietic cells . Blood 86: 101 - 110, 1995.
14. Wells S, Malik P, Pensiero M, Kohn DB, Nolta JA. The presence of an autologous marrow stromal cell layer increases glucocerebrosidase gene transduction of long-term culture initiating cells (LTCIC) from the bone marrow of a patient with Gaucher disease. Gene Therapy 2, 512 - 520, 1995.
15. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett GA, Wells S, Shaw K, Moen RC, Bastian J, Elder M, Wara D, Bowen T, Hershfield MS, Mullen CA, Blaese RM, and Parkman R. Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency. Nature Medicine 1 (10), 1017 - 1023, 1995.
16. Nolta JA, Dao MA, Wells S, Smogorzewska EM, and Kohn DB. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune deficient mice. Proc. Natl. Acad. Sci. USA 93, 2414-2419, 1996.
17. Dao MA, Hannum CH, Kohn DB, and Nolta JA. FLT3 Ligand Preserves the Clonogenic Capacity of Primitive Human Hematopoietic Cells During Ex-vivo Retroviral-mediated Transduction. Blood 89: 446 - 456, 1997.
18. Dao MA and Nolta JA. Inclusion of IL-3 During Retroviral-Mediated Transduction on Stromal Support Does Not Increase the Extent of Gene Transfer Into Long-Term Engrafting Human Hematopoietic Progenitors. Cytokines, Cellular and Molecular Therapy 3: 81 - 89, 1997.
19. Dao MA, Yu XJ, and Nolta JA. Clonal diversity of primitive human hematopoietic progenitors following retroviral marking and long-term engraftment in immune deficient mice. Experimental Hematology 25: 1357-1366, 1997.
20. Dao MA, Pepper KA, and Nolta JA. Long-term cytokine production from engineered primary human stromal fibroblasts influences human hematopoiesis in an in vivo xenograft model. Stem Cells 15: 443 - 454, 1997.
21. Dao MA and Nolta JA. Hematopoietic stem cells as targets for human Gene Therapy: Minireview. Invited review: Cancer Research, Therapy and Control 7:19-25, 1998.
22. Dao MA and Nolta JA. Use of the bnx/hu xenograft model of human hematopoiesis to optimize methods for retroviral-mediated stem cell transduction. International Journal of Molecular Medicine 1: 257-264, 1998.
23. Dao MA, Shah AJ, Crooks GM, and Nolta JA. Engraftment and Retroviral Marking of CD34+ and CD34+CD38- Human Hematopoietic Progenitors Assessed in Immune-Deficient Mice. Blood 91:1243- 1255, 1998.
24. Kohn DB, Hershfeld MS, Carbonaro D, Shigeoka A, Nolta JA, Smogorzewska EM, Barsky L, Chan R, Annett G, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Bastian J, Madsen E, Muul L, Blaese RM, Weinberg K, and Parkman R. T lymphocytes with a normal ADA gene accumulate
35 after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nature Medicine 4: 775-780, 1998.
25. Dao MA and Nolta JA. Xenograft models for gene therapy: Review Article. International Journal of Molecular Medicine 1:257-264, 1998.
26. Dao MA, Taylor N, and Nolta JA. Reduction in levels of the cyclin-dependent kinase inhibitor p27kip-1 coupled with TGFB neutralization induces cell cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc. Natl. Acad. Sci. USA 95: 13006-11, 1998.
27. Dao MA, Hashino K, Kato I, and Nolta JA. Adhesion to fibronectin maintains regenerative capacity during ex-vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood 92: 4612-4621,1998.
28. Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin J, Pensiero M, Emmons RVB, Leitman S, Krebs CB, Carter CC, Brady RO, and Karlsson S. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Human Gene Therapy 9: 2692-2640, 1998.
29. Dao MA, Tsark E, and Nolta JA. Animal xenograft models for evaluation of gene transfer into human stem cells. Current Opinion in Molecular Therapeutics 1:553-557, 1999.
30. Epstein A, Nolta JA, and Durden D. Cbl functions downstream of SRC kinases in FcgammaRI signaling in primary human macrophages. Journal of Leukocyte Biology, 65: 1-12, 1999.
31. Dao MA and Nolta JA. Molecular control of cell cycle progression in primary human hematopoietic stem cells: methods to increase levels of retroviral - mediated transduction. Leukemia 13: 1473 - 80, 1999.
32. Dao MA and Nolta JA. Immunodeficient mice as models of human stem cell engraftment. Current Opinion in Immunology 11: 532 - 537, 1999.
33. Arakawa-Hoyt J, MA Dao, F Thiemann, QL Hao, DC Ertl, KI Weinberg, GM Crooks, and Nolta JA. The number and generative capacity of human B lymphocyte progenitors, measured in vitro and in vivo, is higher in umbilical cord blood than in adult or pediatric bone marrow. Bone Marrow Transplantation 24: 1167 - 1176, 1999.
34. Parkman R, Weinberg K, Crooks G, Nolta JA, Kapoor N, and Kohn D. Gene therapy for adenosine deaminase deficiency. Annual Review of Medicine 51:33-47, 2000.
35. Dao MA and Nolta JA. CD34: To select or not to select? That is the question. Leukemia, 14: 773- 776, 2000.
36. Evans Me, Jordan CT, Nolta, JA, Wivel NA et al. Clinical Infection Control in Gene Therapy. Infection Control and Hospital Epidemiology 21: 659 – 673, 2000.
36 37. Nolta JA, Jordan CT. Spotlight on hematopoietic stem cells: looking beyond dogma. Leukemia. Nov;15(11):1677-80, 2001.
38. Nolta, JA. Cell - Based Therapy: will it replace pharmaceuticals in some cases? Current Drugs 4:212- 218, 2002.
39. Tsark E, Dao MA, Wang X, Weinberg KI, and Nolta JA. IL-7 enhances the responsiveness of human T cells that develop in the bone marrow of athymic mice. Journal of Immunology, 166: 170 – 181, 2001.
40. Wang X, Dao MA, and Nolta JA. Phenotypic comparison of extrathymic human bone marrow- derived T cells with thymic-selected T cells recovered from different tissues. Clinical Immunology Sep;100(3):339-48, 2001.
41. Manfred Schmidt, Hanno Glimm, Nina Lemke, Arne Muessig, Carsten Speckmann, Sebastian Haas, Phillip Zickler, Nolta JA, Gesa Hoffmann, Christof Kalle. Ann N Y Acad Sci. Jun;938:146-55, 2001.
42. Jordan CT and Nolta JA. Spotlight on hematopoietic stem cells: looking beyond dogma. Leukemia. Nov;15(11):1677-80, 2001.
43. Dao MA, Hwa J, and Nolta JA. Molecular mechanism of TGFB-mediated quiescence in human CD34+ progenitors: Modulation of the cyclin-dependent kinase inhibitor p15ink4. Blood Jan 15;99(2):499-506; 2002.
44. Nolta JA, Thiemann F, Arakawa-Hoyt J, Dao MA, and Crooks GM. Analysis of the engraftment potential of human umbilical cord blood CD34+/38- cells following ex-vivo maintenance on human stroma vs. the AFT024 cell line. Leukemia 16; 352-361, 2002.
45. Gussoni E, Meyerrose TE, Nolta JA, Weinberg KA, Kunkel LM, et al. Detection of Donor Nuclei in the Muscles of a Duchenne Muscular Dystrophy Patient 13 Years Following Bone Marrow Transplantation. Journal of Clinical Investigation Sept.; 110(6):807-14, 2002.
46. MA Dao, Arevalo JA, and JA Nolta. Reversibility of CD34 expression on human stem cells that retain the capacity for secondary reconstitution. Blood Jan 1; 101(1); 112-118, 2003.
47. Wu G, Nolta JA, Starnes V, and Cramer D. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation Mar 15; 75(5): 679-685, 2003.
48. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviere I, Blau CA, Richard RE, Sorrentino B, Nolta J, Malech H, Brenner M, Cornetta K, Cavagnaro J, High K, Glorioso J. American Society of Gene Therapy ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy 2003 Aug;8(2):180-7.
49. Bauer G, Nolta JA, Walker JE, Devine S, DiPersio J. Design and construction of a GMP facility for cellular and gene therapy in an academic center-implementing new regulatory requirements. Stem Cell and Cellular Therapy 1:54-61, 2003.
37 50. Schmidt M, Carbonaro D, Speckmann C, Bohnsack J, Nolta JA, Kohn D, von Kalle C. Clonality Analysis after retroviral–mediated gene transfer to cord blood CD34+ cells of an ADA-deficient SCID infant. Nature Medicine, Apr1; 9(4); 463-68, 2003.
51. Meyerrose TE, Herrbrich P, Hess DA, Nolta JA. Immune-deficient mouse models for analysis of human stem cells. Biotechniques. 2003 Dec;35(6):1262-72.
52. Wang X, Ge S, McNamara G, Hao QL, Crooks GM, and Nolta JA. Albumin-expressing hepatocyte- like cells develop in the livers of immune-deficient mice transplanted with highly purified human stem cells. Blood, May 15; 101 (10): 4201-4208, 2003.
53. J Bonde, D Hess, J Nolta. Recent advances in hematopoietic stem cell biology. Current Opinion in Hematology, 11(6):392-8, 2004.
54. Mohamedali A, Moreau-Gaudry F, Richard E, Xia P, Nolta J, Malik P. Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells. Molecular Therapy 2004 Aug;10(2):249-59.
55.DA Hess, TE Meyerrose, L Wirthlin, MH. Creer, PE. Herrbrich, TP. Craft, JA. Nolta. Functional characterization of highly purified human hematopoietic repopulating cells isolated based on aldehyde dehydrogenase activity. Blood, Sept.104:1648-55, 2004.
56.Smith E, Meyerrose T, Kohler T, Namdar-Attar M, Bab N, Lahat O, Noh T, Li J, Karaman M, Hacia J, Chen TT, Nolta JA, Muller R, Bab I, Frenkel B. Leaky ribosomal scanning in mammalian genomes: significance of histone H4 alternative translation in vivo. Nucleic Acids Res. Mar 01;33(4):1298-308, 2005.
57.Sohara Y, Shimada H, Minkin C, Erdreich-Epstein A, Nolta JA, DeClerck YA. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res. Feb 15;65:1129-35, 2005.
53.Hess DA, Wirthlin L, Craft T, Hohm S, Lahey R, Eades WC, Creer MH, Nolta JA. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood, March 1; 107(5):2162-9, 2006.
54.Dao MA and Nolta JA. Cytokine and integrin stimulation synergize to promote higher levels of GATA-2, c-myb, and CD34 protein in primary human hematopoietic progenitors from bone marrow. Blood.109(6):2373-9, Mar 15, 2007.
55.Meyerrose TE, DeUgarte DA, Hofling A, Herrbrich P, Sands MS, Hedrick MA, and Nolta JA. In vivo Distribution of Adipose-Derived Mesenchymal Stem Cells in Novel Xenotransplant Models. Stem Cells.; 25; 220-227, 2007.
56.Partlow KC, Brant J, Chen J, Meyerrose TE, Nolta JA, Caruthers S, Lanza G, and Wickline SA. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. Jun;21(8):1647-54, 2007.
38 57.Hess DA, Bonde J, Wirthlin L, Dipersio J, Devine S, Nolta J. Human progenitors rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased efficiency compared to G-CSF-mobilized cells. Biol.Blood MarrowTransplnt 13:398-411, 2007.
58.Dao MA, Nolta JA, Creer MH, Verfaillie CM. Biology of umbilical cord blood progenitors in bone marrow niches. Mar 19. Blood Jul 1;110(1):74-81, 2007.
59.S X. Qiu, C Dan, L-S Ding, S Peng, S-N Chen, N Farnsworth, J Nolta, M Gross, Ping Zhou. A Triterpene Glycoside from Black cohosh that Inhibits Osteoclastogenesis by Modulating RANKL and TNF Signaling Pathways. Chem Biol. 14:860-9, 2007.
60.B. Nervi, M. Rettig, J. Ritchey, J. Walker, J. Nolta, G. Bauer, J. DiPersio. A new model for GvHD: naïve and ex-vivo activated human T cells generate consistent engraftment and lethal disease in NOD/SCID/B2M null mice. Exp Hem. Dec;35(12):1823-38, 2007.
61.D. Maxwell, J. Bonde, D. Hess, M. Creer, R. Lahey, D. Piwnica-Worms, and J. Nolta. Fluorophore- conjugated iron oxide nanoparticle labeling and analysis of engrafting human stem cells. Stem Cells. Feb;26(2):517-24. 2008.
62. Louisa Wirthlin, David Hess, Ping Zhou, and Jan Nolta. Human Stem Cells for Tissue Repair. Biol Blood Marrow Transplant. Jan;14:151-3, 2008.
63.D. Hess, T. Craft, L. Wirthlin, W. Eades, M. Creer, M. Sands, J. Nolta. Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells. Mar;26(3):611-20. 2008.
64.G Bauer, M Dao, S Case, P Herrbrich, J Arevalo, T Meyerrose, X Wang, S Csik, D Skelton, D B. Kohn, and J Nolta. In Vivo Biosafety Model to Assess Risk of Adverse Events from Retroviral and Lentiviral Vectors. Mol Ther. Jul;16(7):1308-15, 2008.
65.T Meyerrose, M Roberts, K Ohlemiller, C Vogler, L Wirthlin, J Nolta, M Sands. Lentiviral- transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplant model of human disease. Stem Cells.26:1713-22. 2008.
66.Zhou P, Hohm S, Capoccia B, Link D, and Nolta JA. Immunodeficient mouse models to study human stem-cell mediated repair of tissue injury. Methods Mol Biol; 430:213-25, 2008.
67.J.Rich, I. Rosova, J. Nolta, T. Myckatyn, L. Sandell, A. McAlinden. Upregulation of Runx2 and Osterix during in vitro chondrogenesis of human adipose-derived stromal cells. Biochem Biophys Research Com. Jul 18;372(1):230-5. 2008.
68.Rosová I, Dao MA, Capoccia BJ, Link DC, Hess DA, Nolta JA. Hypoxic Preconditioning Results in Increased Motility and Improved Therapeutic Potential of Human Mesenchymal Stem Cells. Stem Cells Aug;26(8):2173-82. 2008.
69.P. Zhou, L. Wirthlin, J. McGee, G. Annett, and J. Nolta. Contribution of human hematopoietic stem cells to liver repair. Seminars in Immunopathology Sep;31(3):411-9. Epub 2009 Jun 17. 2009.
39 70.P. Zhou, R. Lahey, S. Hohm, D. Hess, J Nolta. Liver Engraftment by Transplanted Human Cord Blood Progenitors and Human embryonic Stem Cells in a Novel Model, the NOD/SCID/MPSVII Mouse. Hepatology 49 (6): 1992 – 2000, 2009.
71.Capoccia BJ, Robson DL, Levac KD, Maxwell DJ, Hohm SA, Neelamkavil MJ, Bell GI, Xenocostas A, Link DC, Piwnica-Worms D, Nolta JA, Hess DA. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 21 May, 113 ( 21): 5340-5351, 2009.
72.Anderson JS, Javien J, Nolta JA, Bauer G. Preintegration HIV-1 Inhibition by a Combination Lentiviral Vector Containing a Chimeric TRIM5alpha Protein, a CCR5 shRNA, and a TAR Decoy. Molecular Ther apy 2009 Dec;17(12):2103-14. Epub 2009.
73.Anderson J, Nolta JA, Bauer G. Specific Transduction of HIV-Susceptible Cells for CCR5 Knockdown and Resistance to HIV Infection: A Novel Method for Targeted Gene Therapy and Intracellular Immunization. Journal of Acquired Immune Deficiency Syndromes Oct 1;52(2):152-61, 2009.
74. Nolta J. Working Toward Mesenchymal Stem Cell Therapy for HD. Neurotherapeutics Volume 7, Issue 1, pp 136-137, 2010.
75.C Sondergaard, D Hess, D Maxwell, C Weinheimer, I Rosová, M Creer, D Piwnica-Worms, A Kovacs, L Pedersen, and J Nolta. Human UCB Progenitors with High ALDH Activity Improve Vascular Density in Acute Myocardial Infarction. In press, Journal of Translational Medicine, 2010.
76.Annett G, Olson S, Wirthlin L, Bauer G and Nolta J. Mesenchymal Stem Cells for the Treatment of Neurodegenerative Diseases. In press, Regenerative Medicine 2010.
77.I. Rosová, D. Link, and J. Nolta. Small Interfering RNA-Mediated Decreases in c-Met Levels Affect the Differentiation Potential of Human Mesenchymal Stem Cells and Reduce Their Capacity for Tissue Repair. In press, Tissue Engineering 2010.
Abstracts 1. Kohn DB, Nolta JA. Expression of the human glucocerebrosidase gene by retroviral vectors. Presented at the UCLA Symposium on Gene Transfer in Animals, Tamarron, CO, February 1988.
2. Kohn D, Nolta J, Stephens D, Jacobs K, Rossi JJ, Zaia JA. Retroviral vectors producing HIV antisense RNA block HIV infection. Blood 72 (Suppl 1):355a, 1988.
3. Sender LS, Nolta JA, Barranger JA, Kohn DB. Human glucocerebrosidase gene transfer by retroviral vectors. Pediatr Res 25:145a, 1989.
4. Nolta JA, Sender LS, Barranger JA, Kohn DB. Retroviral-mediated transfer of the human glucocerebrosidase gene. Blood 72 (Suppl 1):398a, 1988.
5. Kohn DB, Nolta JA, Rossi JJ, Zaia JA. Retroviral vectors producing HIV antisense RNA block
40 HIV infection. Pediatric Research 25:182a, 1989.
6. Ozkaynak MF, Nolta JA, Gomer C, Reynolds CP, Seeger R, Parkman R. Ex vivo purging of rhabdomyosarcoma cells from the bone marrow using merocyanine-540 (ME-540) or 4- Hydroperoxycyclophosphamide (4-HC). Presented at American Society of Pediatric Hematology/Oncology, Chicago, September 1989.
7. Lenarsky C, Nolta J, Weinberg K, Kohn D, Parkman R. Recombinant human granulocyte macrophage colony stimulating factor (rGM-CSF) induced hematopoiesis following rejection of a bone marrow transplant (BMT). Pediatr Res 25:153a, 1989.
8. Kohn DB, Nolta JA, Sender LS, Barranger JA. Human glucocerebrosidase gene transduction into hematopoietic cells by retroviral vectors. Blood 74:204a, 1989.
9. Nolta JA, Kohn DB. Hematopoietic growth factors increase retroviral vector-mediated gene transfer into human progenitor cells. Blood 74 (Suppl 1):233a, 1989.
10. Kohn DB, Nolta JA. Efficient gene transfer by a retroviral vector into human hematopoietic progenitor cells. Pediatric Research 27: 163a, 1990.
11. Weinthal J, Nolta JA, Sender LS, Uribe L, Barranger JA, Kohn DB. Expression of human glucocerebrosidase in hematopoietic cells by retroviral vectors. Pediatric Research 27:137a, 1990.
12. Tishler DM, Nolta JA, Raffel C. Multiple drug resistance gene (MDR-1) expression in childhood PNET. Presented at the International Symposium on Pediatric Neuro-Oncology, Philadelphia, PA, May 1990.
13. Nolta JA, Kohn DB. Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative status of human hematopoietic progenitor cells. Experimental Hematology 18:282a, 1990.
14. Nolta JA, Kohn DB. Highly efficient gene transfer by a retroviral vector into human hematopoietic progenitor cells. Experimental Hematology 18:262a, 1990.
15. Lenarsky C, Weinberg K, Kohn D, Sender L, Brooks J, Annett G, Nolta J, and Parkman R. Bone marrow transplantation (BMT) for children with acute lymphoblastic leukemia (ALL) without total body irradiation (TBI). Blood 76 (Suppl 1):549a, 1990.
16. Nolta J, Bahner I, Crooks G, Yu XJ, Kohn DB (Intr. by R. Parkman). Glucocerebrosidase (GC) gene transduction of human gaucher bone marrow in long term bone marrow culture (LTBMC). Blood 76 (Suppl 1):561a, 1990.
17. Weinthal J, Nolta JA, and Kohn DB. Expression of human glucocerebrosidase in hematopoietic cells by retroviral vectors. Experimental Hematology 18:293a, 1990.
18. Nolta J, Weinthal J, Sender LS, and Kohn DB. Analysis of glucocerebrosidase (GC) gene transduction in murine long term bone marrow culture (LTBMC). Blood 76 (Suppl 1):558a, 1990.
41 19. Kohn DB, Nolta JA, Yu XJ. Glucocerebrosidase (GC) gene transduction of human gaucher bone marrow. Ped Research 29:131A, 1991.
20. Weinthal J, Nolta J, Yu X.Y, Lilley J, and Kohn D. Human glucocerebrosidase expression in murine BMT recipients: optimizing stem cell transduction using retroviral vectors. Blood 76 (Suppl 1):572a, 1990.
21. Nolta JA, Weinthal J, Crooks GM, Challita PM, Williams DE, Overell RW, and Kohn DB. Effects of mast cell growth factor (MGF) on retroviral vector-mediated gene transfer into primitive hematopoietic progenitors. Blood 78 (Suppl 1):374a, 1991.
22. Lenarsky C, Weinberg K, Kohn DB, Sender L, Brooks J, Annett G, Nolta J, and Parkman R. Bone marrow transplantation (BMT) for children with acute lymphoblastic leukemia (ALL) with busulfan (BU) and cyclophosphamide (CY). Blood 78 (Suppl 1):239a, 1991.
23. Nolta JA, Yu XJ, Bahner I, and Kohn DB. Glucocerebrosidase gene transduction of cultured Gaucher marrow. Experimental Hematology 20:346a, 1992.
24. Crooks GM, Nolta JA, Hanley M, Lyons RM, Moen RC, and Kohn DB. Growth factors increase binding of amphotropic retrovirus to CD34+ human bone marrow progenitors. Blood 80 (Suppl 1) 24a, 1992.
25. Fackler MJ, Nolta JA, Kohn DB, May WS, and Civin CI. Physiological activators of PKC can induce CD34 hyperphosphorylation. Blood 80 (Suppl 1) 296a, 1992.
26. Nolta JA, Hanley ME, and Kohn DB. Co-transplantation of human marrow stromal cells producing IL-3 with CD34+ progenitor cells supports persistent human myelopoiesis in immunodeficient mice. Blood 80 (Suppl 1): 269a. 1992.
27. Nolta JA, Hanley M, and Kohn DB. In vivo system to assess the efficiency of retroviral-mediated transduction of primitive human HSC. Blood 82 (Suppl 1):1371, 1993.
28. Nolta JA and Kohn DB. In vivo model for analysis of retroviral-mediated transduction of primitive human hematopoietic cells. Expt. Hem. 22:698, 1994.
29. Fackler MJ, Smith OM, Krause DS, Nolta JA, Civin CI, and May WS. Inhibition of hematopoietic differentiation by enforced expression of full-length CD34 occurs in CD34-positive but not CD34- negative cell lines. Blood 84 (Suppl 1):1658, 1994.
30. Nolta JA, Smogorzewska EM, and Kohn DB. Late graft failure in immunodeficient mice by human CD34+ progenitors transduced without stromal support. Blood 84:1357, 1994.
31. Wells S, Pensiero M, Kohn DB, and Nolta JA. Glucocerebrosidase gene transduction of Gaucher bone marrow is optimized by stromal support. Blood 84 (Suppl 1):1416, 1994.
32. Krall W, Challita PM, Nolta JA, Riviere I, Lehn P, Ginns EI, Mulligan RC, Kohn DB. Direct comparison of an MFG-based vector to an N2-based vector in primary hematopoietic cells. J. Cell. Biochem. 18A:251, 1994.
42 33. Kohn DB, Weinberg KI, Parkman R, Lenarsky C, Crooks GM, Nolta JA, Shaw K, Hanley ME, Lawrence K, Annett G, Brooks JS, Wara D, Elder M, Bowen T, Hershfield MS, Berenson RI, Moen RC, Mullen CA, Blaese RM. Gene therapy for neonates with ADA-deficient SCID by retroviral-mediated transfer of the human ADA cDNA into umbilical cord CD34+ cells. J. Cell. Biochem. 18A:238, 1994.
34. Kohn D, Weinberg K, Lenarsky C, Crooks GM, Nolta JA, Hanley ME, Lawrence K, Annett G, Wara D, Elder M, Bowen T, Hershfield MS, Moen RC, Mullen CA, Blaese RM, Parkman R. Gene therapy for neonates with adenosine deaminase (ADA) deficient SCID by retroviral-mediated transfer of the human ADA cDNA into umbilical cord CD34+ cells. Ped. Research 35:900a, 1994.
35. Nolta JA, Dao, MA, Smogorzewska EM, Wells S, and Kohn DB. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune deficient mice. Experimental hematology 23: 892, 1995.
36. Arevalo J., Nolta JA, Parkman R. Human multiple drug resistance gene transfer into human hematopoietic progenitors. J. Cell. Biochem. 21: C6-502a, 1995.
37. Kohn DB, Weinberg KI, Lenarsky C, Crooks GM, Nolta JA, Wara D, Bowen T, Hershfield M, Blaese RM, Parkman R. Gene therapy for neonates with ADA deficiency by transfer of the ADA cDNA into umbilical cord blood cells: two years follow-up. Pediatric Research 9A, 37,1995.
38. Dao MA, Nolta JA, Hannum C, and Kohn DB. FLT3 ligand preserves viability of human hematopoietic stem cells during in vitro transductions. Blood 86 (Suppl. 1):423a,1995.
39. Kohn DB, Weinberg KI, Lenarsky C, Crooks GM, Nolta JA, Bastian J, Wara D, Elder M, Bowen T, Hershfield M, Blaese RM, Parkman R. Selective accumulation of ADA gene - transduced T lymphocytes upon PEG-ADA dosage reduction after gene therapy with transduced CD34+ umbilical cord blood cells. Blood 86: 295a,1995.
40. Nolta JA, Dao MA, Smogorzewska EM, Wells S, and Kohn DB. Retroviral - mediated transduction of pluripotent human stem cells verified by clonal analysis after differentiation in immune deficient mice. Blood 86 (Suppl. 1): 296a, 1995.
41. Kohn DB, Challita PM, Malik P, and Nolta JA. Gene transfer for Gaucher disease. J. Cellular Biochemistry 21: C6-125a, 1995.
42. Kohn DB, Weinberg KI, Lenarsky C, Crooks GM, Nolta JA, Elder M, Bowen T, Hershfield M, Blaese RM, Parkman R. Transfer of the ADA cDNA into umbilical cord blood CD34+ cells in a clinical trial for ADA deficiency diagnosed in utero. American Pediatrics/SPR 130a, 1995.
43. Bolotin E, Nolta J, Smith S, Dao M, Weinberg K. Effective immune reconstitution in mice after co-transplantation of bone marrow and marrow stroma transduced with the IL-7 gene: Gene therapy for post-BMT immune deficiency. Pediatric Research 39:40a, 1995.
44. Dao MA and Nolta JA. Clonal diversity of vector-marked human hematopoietic progenitors
43 recovered from long-term engrafted immune deficient mice. Expt. Hematology 24; 1056, 1996.
45. Nolta JA, Dao MA, Pepper KA, and Kohn DB. Stromal cells engineered to produce cytokines support multilineage human hematopoiesis in immune deficient mice. Keystone Symposium on Hematopoietic Microenvironment, p. 168, 1996.
46. Nolta JA, Dao MA, Yu XJ, and Kohn DB. Proviral integration site analysis of marked human hematopoietic stem cells engrafted long-term in immune deficient mice. Keystone Symposium on Hematopoietic Stem Cell Gene Therapy, p. 134, 1996.
47. Dao MA, Hannum C, Kohn DB, and Nolta JA.The viability of primitive human hematopoietic progenitors is maintained by inclusion of FLT3 ligand in 72-hour transductions. Keystone Symposium;Hematopoietic Stem Cell Gene Therapy, p. 177, 1996.
48. Parkman R, Masinsin B, Nolta JA, Dao MA, Weinberg KI, and Kohn DB. Analysis of T lymphocytes from patients with adenosine deaminase deficiency transplanted with ADA transduced cord blood cells. Keystone Symposium on Hematopoietic Stem Cell Gene Therapy, p.5, 1996.
49. Kohn DB, Weinberg KI, Lenarsky C, Crooks GM, Heiss LN, Nolta JA, Wara D, Elder M, Bowen T, Hershfeld M, Blaese RM, and Parkman R. Selective accumulation of ADA gene-transduced T lymphocytes upon PEG-ADA dosage reduction after gene therapy with transduced CD34+ umbilical cord blood cells. Keystone Symposium on HSC Gene Therapy, p.18,1996.
50. Dao MA and Nolta JA. An in vivo system to trace the progeny of transduced pluripotent human hematopoietic stem cells. ASBMT 2:11, 1996.
51. Dao MA, Williams DA, and Nolta JA. High efficiency transduction of human CD34+ progenitors on fibronectin CH-296 verified by clonal integration analysis. Expt. Hematology 24 (9) 1057, 1996.
52. Dao MA, Pepper KA, and Nolta JA. Human cytokine production from engineered stromal cells influences lineage development from co-transplanted human CD34+ progenitors. Experimental Hematology 24; 1117, 1996.
53. Bolotin E, Nolta J, Smith S, Dao M, and Weinberg K. Effective immune reconstitution in mice after co-transplantation of bone marrow and marrow stroma transduced with the IL-7 gene: gene therapy for post-BMT immune deficiency. Presented in a platform session at the 1996 Pediatric Academic Societies Annual Meeting, Washington, DC, May, 1996.
54. Dao MA, Shah AJ, Smogorzewska EM, Crooks GC, and Nolta JA. Comparison of human hematopoietic progenitor content and retroviral marking in immune deficient mice transplanted with CD34+ vs. CD34+/38- cells. Blood 88 (10) 428a, 1996.
55. Dao MA, and Nolta JA. Inclusion of IL-3 during retroviral-mediated transduction on stromal support does not increase the extent of gene transfer into long-term engrafting human hematopoietic progenitors. Blood 88 (10) 428a, 1996.
44 56. Bolotin E, Nolta J, Smith S, Dao M, and Weinberg K. Gene therapy with marrow stroma transduced with the IL-7 gene rapidly restores immune function after murine bone marrow transplant. Blood 88 (10) 298a, 1996.
57. Almeida-Porada GD, Nolta JA, Dao MA, Tran N, and Zanjani ED. Enhancement of donor (human) hematopoietic stem cell (HSC) engraftment in sheep co-transplanted in utero with human IL-3 producing stroma. Blood 88 (10) 186a, 1996.
58. Dao MA and Nolta JA. Effects of TGFB neutralization on transduction and expansion of human hematopoietic cells. Keystone Symposium on Hematopoiesis, p.179, 1997.
59. Dao MA and Nolta JA. Molecular mechanism of TGFB-mediated quiescence in human CD34+ progenitors on fibronectin. Keystone Symposium on Signal Transduction by Cell Adhesion Receptors, p. 135, 1997.
60. Dao MA and Nolta JA. In vivo model to test improved methods for introduction of DNA into pluripotent human hematopoietic stem cells. Acta Haematologica 98:30, 1997.
61. Dao MA and Nolta JA. Retroviral - mediated transduction of human hematopoietic stem and progenitor cells measured in a long-term xenograft assay. Vectors: from Biology to Technology, p.45, 1997.
62. Dao MA and Nolta JA. Modulation of the extent of retroviral-mediated transduction of human hematopoietic progenitors by positive and negative regulators of cell cycle. International Society of Hematology, p. 254, 1997.
63. Dao MA and Nolta JA. Effect of TGFB on human CD34+ progenitors on fibronectin, at the cell cycle level. Expt. Hem.25: 753, 1997.
64. Dao MA and Nolta JA. Increased efficiency of transduction of CD34+ progenitors by neutralization of TGFB in serum-free medium on fibronectin support. Expt.Hem.25:893, 1997.
65. Dao MA and Nolta JA. Modulation of cell cycle in primary human CD34+ hematopoietic progenitors by antisense oligonucleotides to cyclin-dependent kinase inhibitors. Expt. Hem. 25: 881, 1997.
66. Dao MA and Nolta JA. Improvement in retroviral - mediated transduction of quiescent human hematopoietic progenitors through a combination of neutralization of TGFB and antisense oligonucleotides to the CDK inhibitor p27 kip-1. Blood 90: 600, 1997.
67. Dunbar CE, Kohn DB, Schiffman R, Barton NW, Nolta JA, Esplin J, Pensiero M, Emmons RB, Leitman S, Kreps CB, carter C, Brady RO, and Karlsson S. Retroviral gene transfer of the glucocerebrosidase gene into Peripheral Blood or BM CD34+ cells from patients with Gaucher disease: results from a clinical trial. Blood 90: 404, 1997.
68. Retroviral gene transfer of the glucocerebrosidase gene into PB or BM CD34+ cells from patients with Gaucher disease: results from a clinical trial. CE Dunbar, DB Kohn, R Schiffman, NW Barton, J Nolta, S Wells, J Esplin, M Pensiero, RVB Emmons, S Leitman, CB Kreps, C Carter, J
45 Kimball, NS Young, RO Brady, and S Karlson. Blood 90: 237, 1997.
69. Biochambers containing S17 stromal cells and human CD34+ cells implanted to study the lack of human B lymphocyte development in bnx/hu mice. DC ErtL, MA Dao, QL Hao, J Andrades, M Nimni, P Pattengale, GM Crooks, and JA Nolta. Blood 90: 3493, 1997.
70. Dao MA and Nolta JA. Induction of cell cycle entry by decreasing levels of the cyclin-dependent kinase inhibitors p15INK4B and p27 KIP1 in quiescent hematopoietic progenitors. Cell Cycle (Keystone Symposium) 39: 114, 1998.
71. J Arakawa-Hoyt, F Thiemann, MA Dao, QL Hao, DC Ertl, KI Weinberg, GM Crooks,and JA Nolta. B Lymphocytes develop in beige/nude/xid (bnx) mice from human umbilical cord blood, but not bone marrow. Experimental Hematology 26;749, 1998.
72. JA Nolta, J Arakawa-Hoyt, MA Dao, L Barsky, and K Weinberg. Development of IL-2 responsive human T lymphocytes in bnx mice after transplantation of CD34+ progenitors from X-SCID patients transduced with a normal gamma c gene. American Society for Gene Therapy, First Annual Meeting in Seattle, WA, May 1998.
73. MA Dao and JA Nolta. The duration of ex-vivo culture has a profound effect on the ability of human bone marrow stem cells to generate B cells after transplantation. Blood 92: 125a, 1998.
74. MA Dao and JA Nolta. Treatment With Anti-TGFB Antibody (Ab) and Anti-p27 Oligonucleotides (ON) Recruits Quiescent Hematopoietic Progenitors Into Cycle While Maintaining Their Multipotentiality. Experimental Hematology 26; 687, 1998.
75. JA Nolta, J Arakawa-Hoyt, MA Dao, L Barsky, J Puck, and KI Weinberg. IL-2 - Responsive human T lymphocytes develop in bnx mice from X-SCID CD34+ progenitors transduced with a normal c gene. Experimental Hematology 26; 806, 1998.
76. MA Dao, JA Nolta. Reduction in levels of the CDK inhibitors p15 ink4b and p27 kip-1 allows transduction of primitive, reconstituting hematopoietic cells. Received Merit Award at the 40th annual meeting of the American Society for Hematology. Blood 92: 521a, 1998.
77. DC Ertl, MA Dao, KA Pepper, and JA Nolta. Primary human stromal cells engineered to secrete human erythropoietin (hEpo) promote terminal human red blood cell maturation in bnx/hu mice. Blood 92: 718a, 1998.
78. Arakawa-Hoyt, JS, Thiemann FT, Dao MA, Barsky L, Crooks GM, and Nolta JA. The AFT024 stromal line supports long-term ex-vivo maintenance of engrafting multipotent human hematopoietic progenitors. Blood 92: 2397, 1998.
79. Tsark E, Dao MA, and Nolta JA. Impaired activation of human T lymphocytes recovered from bnx/hu mice in response to either anti-CD3 + anti-CD28 antibodies or to PMA + ionomycin. Blood 92: 642a, 1998.
80. Nolta JA, Arakawa-Hoyt J, Dao MA, Barsky L, Puck J, and Weinberg KI. Development of IL-2
46 responsive human T lymphocytes in bnx mice after transplantation of CD34+ progenitors from X-
SCID patients transduced with a normal c gene. Blood 92: 666a, 1998.
81. Mo A. Dao and Jan A. Nolta. Molecular control of cell cycle progression in primary human hematopoietic cells. Molecular Biology of the Cell 7: 1395a, 1998.
82. Tsark E, Dao MA, and Nolta JA. Human T lymphocytes are hyporesponsive to stimulation following recovery from immune deficient mice. Presented in poster format at the 1998 Keystone Symposium; Bone Marrow Transplantation.
83. Mo Dao and Jan Nolta. TGFB Mediates Inhibition of Hematopoietic Progenitor Cell Cycle by Decreasing levels of Cyclin D2 and Increasing levels of p15INK4B. Presented in poster format at the 1999 Keystone Symposium; Oncogenes.
84. Arevalo JM, Ertl DC, Dao MA, Shultz LD, and Nolta JA. A new immunodeficient mouse strain: the nude/NOD/SCID mouse, for human hematopoietic cell transplantation. Poster presentation, American Society of Hematology. Blood 94 (10) Suppl 1, 129a, 1999.
85. Dao MA and Nolta JA. Adhesion to Fibronectin causes alterations in the subcellular localization of the MAPKs ERK1 and ERK2 in primary CD34+ cells. Poster presentation, American Society of Hematology. Blood 94 (10) Suppl 1, 42a, 1999.
86. Dao MA, Arakawa-Hoyt, JA, Ertl DC, Tsark E, Shultz LD, and Nolta JA. 5-Fluorouracil used as a sublethal conditioning agent allows human hematopoietic cell homing and engraftment in beige/nude/xid mice. Poster presentation, American Society of Hematology. Blood 94 (10) Suppl 1,129a, 1999.
87. Hao QL, Barsky W, Yao D, Bockstoce D, Payne KJ, Petersen D, Ertl DC, Amis J, Nolta JA, Parkman R, Weinberg KI, and Crooks GM. Functionally different subpopulations of CD34+/CD38- hematopoietic progenitors are defined by differential common gamma chain expression. Poster presentation, American Society of Hematology. Blood 94 (10) Suppl 1, 253a, 1999.
88. Ertl DC, Hao QL, Halene S, Shultz LD, and Nolta JA. Variance in generation of human T lymphocyte subsets in different strains of immune deficient mice and fetal thymic organ culture. Poster presentation, American Society of Hematology. Blood 94; 9a, 1999.
89. Dao MA and Nolta JA. The carboxy-terminal domain of fibronectin regulates cell cycle entry in primary human CD34+ cells by decreasing cycllin E levels and increasing the association of p27 with CDK2/cyclin A complexes. Poster presentation, American Society of Hematology. Blood 94 (10) Suppl 1, 268a, 1999.
90. Dao MA, Kohn DB, and Nolta JA. The route of delivery of genetically engineered mesenchymal stem cells (MSC) influences differentiation and protein secretion. Poster presentation, American Society of Hematology. Blood 94 (10) Suppl 1, 362a, 1999.
91. MA Dao, DC Ertl, X Wang, TH Kim, P Malik, DB Kohn, and JA Nolta. Human MSC Differentiation and Engineered Protein Secretion in Neo-Organoids is Dependent on Implantation
47 Site. Molecular Therapy 1:S85, 2000.
92. X wang, R Hong, and J Nolta. Extrathymic human T lymphocyte development and regulation in immune deficient mice. Presented as a late-breaking abstract at the 2000 meeting of the International Society of Experimental Hematology, Tampa, Florida.
93. E. Tsark, M. Dao, X. Wang, K. Weinberg, and J. Nolta. MSC Engineered to Secrete huIL-7 Partially Alleviate CD4 to CD8 Imbalance and Anergy in Human T Cells That Differentiate in the Marrow of Athymic Mice. Presented at the American Society for Gene Therapy Conference, Denver, CO, 2000.
94. MA Dao and JA Nolta. Alteration in p27 and p21 protein levels in response to integrin - growth factor mediated signaling in primary human hematopoietic progenitors. Presented at the 2000 Keystone Symposia Meeting on Integrin and Growth Factor Signaling.
95. MA Dao, E Tsark, D Ertl, X Wang, TH Kim, P Malik, DB Kohn, and JA Nolta. Engineered cytokine secretion from human mesenchymal stem cells influences in vivo hematopoiesis. Oral presentation by M. Dao in the New Investigator Award Session at the 2000 meeting of the International Society of Experimental Hematology (ISEH).
96. MA Dao and JA Nolta. Integrin engagement on fibronectin modulates the protein levels of c-myb. CD34, p21, and p130 in primary human hematopoietic progenitors. Oral presentation in the session: cellular interactions and adhesion molecules, at the 2000 meeting of the ISEH.
97. X Wang, R. Hong, and JA Nolta. Extrathymic human T lymphocyte development and regulation in immune deficient mice. Oral presentation in the session of “late breaking abstracts”, at the 2000 meeting of the ISEH. Experimental Hematology 28: 1500, 2000.
98. MA Dao and JA Nolta. Reversibility of CD34 expression on human stem cells that retain the capacity for secondary reconstitution. Blood 96:581a, 2000.
99. E. Tsark, M. Dao, X. Wang, K. Weinberg, and J. Nolta. HuIL-7 secretion from engineered MSC improves CD4 deficiency and partially restores responsiveness in human T cells that differentiate in the marrow of athymic mice. 13th International Meeting of the Molecular Biology of Hematopoiesis, New York, July 14-18, 2000.
100. MA Dao and JA Nolta. Modulation of specific cyclin/CDK complexes in response to integrin engagement: Relation to human stem cell pool maintenance. Blood 96:570a, 2000.
101. TE Meyerrose, TH Kim, DC Ertl, and JA Nolta. Implantation of an engineered mesenchymal stem cell organoid on a biodegradable matrix to produce human erythropoietin in nude/NOD/SCID mice. Blood 96:804a, 2000.
102. JMG Arevalo, SS Case, DB Kohn, and JA Nolta. Effects of allogeneic support cells on human hematopoietic stem cell engraftment in a novel immune deficient mouse transplant system. Blood 96:173a, 2000.
103. JA Nolta, MA Dao, and DB Kohn. Detailed biosafety analyses confirm that there is low risk from
48 MoMuLV-based retroviral vectors. Blood 96:800a, 2000.
104. Q-L Hao, J Zhu, MA Price, KJ Payne, X Wang, D Yao, LW Barsky, JA Nolta, KI Weinberg, and GM Crooks. Differential expression of the common gamma chain (GC) on CD34+CD38- cells allows identification of a quiescent, pluripotent subpopulation. Blood 96:667a, 2000.
105. X Wang, MA Dao, and JA Nolta. Phenotypic comparison of extrathymic human bone marrow- derived T cells with thymic-selected T cells recovered from different tissues. Blood 96:614a, 2000.
106. X Wang, R Hong, and JA Nolta. In vivo study of extrathymic human T lymphocyte development using a novel xenotransplantation model. Blood 96:474a, 2000.
107. Q-L Hao, J Zhu, MA Price, KJ Payne, X Wang, LW Barsky, JA Nolta, and GM Crooks. CD7 expression defines a CD34+CD38- subpopulation with differentiation potential restricted to lymphoid lineages. Blood 96:662a, 2000.
108. F Moreau-Gaudry, M Azim, G Jiang, P Xia, N Perelman, T Meyerrose, J Nolta. P Malik. Long- term transduction and lineage-specific expression of self-inactivating (SIN) lentiviral vectors in murine hematopoietic stem cells. Blood 96:590a, 2000.
109. Mo A. Dao and Jan A. Nolta. Human stem cell pool modulation by integrin engagement. Presented at the Keystone 2001 meeting on Hematopoiesis.
110. Mo A. Dao, Jesusa Arevalo, and Jan Nolta. Human CD34+ cells generate CD34- progeny in vivo, which retain multilineage reconstitution capacity. Presented at the Keystone 2001 meeting on Hematopoiesis.
111. Dao MA and Nolta JA. Effects of the recombinant fibronectin fragment CH-296 on human hematopoietic stem cell cycle, viability, and long term engraftment. Presented at the International Society of Experimental Hematology meeting in Tokyo, Japan, August 25, 2001.
112. X Wang, R Hong, and JA Nolta. In vivo study of extrathymic human T lymphocyte development using a novel xenotransplantation model. American Society of Hematology annual meeting, Orlando, December 2001.
113. Todd Meyerrose, Daniel DeUgarte, Mark Hedrick, and Jan A. Nolta. Tissue Distribution of Human Bone Marrow vs. Adipose-derived Stem Cells in Immune Deficient Mice. American Society of Hematology annual meeting, Orlando, December 2001.
114. Dao MA, Ge S, and Nolta JA. Enhanced transduction of human lymphomyeloid repopulating progenitors by cyclin dependent kinase inhibitor reduction, confirmed by clonal integration analysis. American Society of Hematology annual meeting, Orlando, December 2001.
115. Mo A. Dao, Joseph Hwa, and Jan A. Nolta. Molecular Mechanism of TGFB-Mediated Cell Cycle Modulation in Primary Human CD34+ Progenitors. American Society of Hematology annual meeting, Orlando, December 2001.
116. Xiuli Wang, Shundi Ge, Gay M. Crooks, Qian-Lin Hao, Mary Price, and Jan A. Nolta.
49 Development of Human Albumin-Expressing Cells in the Liver of Immune Deficient Mice Transplanted With Highly Purified Human Hematopoietic Stem Cells. American Society of Hematology annual meeting, Orlando, December 2001.
117. MA Dao, K Xi, S Ge, JA Nolta. Cyclin Dependent Kinase Inhibitor Reduction Enhances Retroviral Transduction of Common Human T Lymphoid and Myeloid repopulating Cells, Confirmed by Single Colony Clonal Integration Analysis. Molecular Therapy 5; S22, 2002.
118. MA Dao, Arevalo JA, and JA Nolta. Reversibility of CD34 expression on human stem cells that retain the capacity for secondary reconstitution. Experimental Hematology 30; 44, 2002.
119. Schmidt M, Carbonaro D, Speckmann C, Wissler M, Bohnsack J, Nolta JA, Kohn DB, and von Kalle C. Clonality Analysis after retroviral – mediated gene transfer to cord blood CD34+ cells from ADA-deficient SCID infants. Molecular Therapy 5; S289, 2002.
120. Xiuli Wang, G. Crooks, QL Hao, Jan A. Nolta. Hepatocyte growth factor increases development of Human Albumin-Expressing Cells in the Livers of Immune Deficient Mice Transplanted With Highly Purified Human Hematopoietic Stem Cells. Experimental Hematology 30; 132, 2002.
121. TE Meyerrose, DA De Ugarte, G McNamara, MH Hedrick, and JA Nolta. Xenotransplant of Human Adipose-Derived Mesenchymal Stem Cells. International Society for Experimental Hematology, annual meeting in Montreal, Canada, 2002. Experimental Hematology 30; 142. Presented by student TM at the Annual Presidential Symposium.
122. TE Meyerrose, AA Hoffling, DA DeUgarte, M Rao, T Cordonnier, I Rosova, G Bauer, C Eagon, M Creer, C Johnson, P Herrbrich, MA Hedrick, MS Sands, and JA Nolta. Human Adipose- Derived Mesenchymal and Adherent Cord Blood Stem Cell Trafficking Studies are Facilitated by Novel Xenotransplant Models. Presented by TM at the American Society of Hematology Annual Meeting, Philadelphia, December 2002.
123. Jon E. Walker, Gerhard Bauer, Phillip Herrbrich, David Hess, Todd Meyerrose, Bruno Nervi, John F. DiPersio, Jan A. Nolta. NOD-SCID 2M Null Mice, a Unique and Highly Permissive Xenograft Model for Studying Human T Cell Activation, Expansion and GvHD Potential In Vivo. Presented at the 43rd annual meeting of the American Society of Hematology, San Diego, CA. Abstract # 3544, Blood 2003.
124. Phillip E. Herrbrich, Todd E. Meyerrose, Marie Roberts, Kenneth I. Weinberg, Mark S. Sands, Jan A. Nolta. Neonatal Transplantation of Unconditioned NOD/SCID/B2M Null Mice To Generate a Thymoma - Free Breeding Colony for Xenotransplantation Studies. Presented at the 43rd annual meeting of the American Society of Hematology, San Diego, CA. Abstract # 5339, Blood 2003.
125. Todd Meyerrose, August Hofling, Taylor Cordonnier, Phillip Herrbrich, Chris Eagon, Mark Sands, Jan A. Nolta. Tissue Localization of Human Hematopoietic and Mesenchymal Stem Cells In Vivo: Rapid Tracking Independent of Cell Surface Protein Expression. Presented at the 43rd annual meeting of the American Society of Hematology, San Diego, CA. Abstract # 1301, Blood 2003.
126. Todd E. Meyerrose, David A. Hess, Phillip E. Herrbrich, Jan A. Nolta. Isolation of Human Aldehyde Dehydrogenase - Expressing Stem Cells; a Population with Increased Homing and
50 Hematopoietic Potential. Presented at the 43rd annual meeting of the American Society of Hematology, San Diego, CA. Abstract # 1175, Blood 2003.
127. David A. Hess, Todd E. Meyerrose, Phillip E. Herrbrich, Jan A. Nolta. Functional characterization of Highly Purified Human Hematopoietic Repopulating Cells Isolated Based on Aldehyde dehydrogenase Activity. Presented at the 43rd annual meeting of the American Society of Hematology, San Diego, CA. Abstract # 383, Blood 2003. Oral presentation.
128. David A. Hess, Louisa Wirthlin, Timothy P. Craft, Todd E. Meyerrose, Jan A. Nolta. CD133- Expressing Cells with High Aldehyde Dehydrogenase Activity Represent a Primitive Human Hematopoietic Stem Cell Population with Enhanced Repopulating Potential. American Society of Hematology Annual meeting, San Diego CA, abstract # 250; Blood December 2004, oral presentation.
129. David A. Hess, Timothy P. Craft, Louisa Wirthlin, Phillip E. Herrbrich, A. Alex Hofling, Mark S. Sands, Jan A. Nolta. Transplantation of Human Aldehyde Dehydrogenase Expressing Cells Leads to Widespread Tissue Distribution of Donor Cells in the Novel NOD/SCID/MPSVII Xenotransplantation Model. American Society of Hematology Annual meeting, San Diego CA, abstract # 3601; Blood December 2004
130. T. Meyerrose, J. Nolta, I. Bab. And B. Frenkel. Enhanced trabecular bone in transenic mice overexpressing osteogenic growth peptide. T. Kohler, Presented by Dr. Frenkel at the 2004 meeting of the SSBE, January 2004.
131. David A. Hess, Phillip E. Herrbrich, Louisa Wirthlin, Timothy P. Craft, Jan A. Nolta. Isolation of Human CD34 - Cells with High Aldehyde Dehydrogenase Activity Reveals a Novel Population with Hematopoietic Repopulating Potential. American Society of Hematology Annual meeting, San Diego CA, abstract # 3214; Blood, December 2004.
132. David A. Hess, Jesper Bonde, Timothy P. Craft, Louisa Wirthlin, John F. DiPersio, Steven M. Devine, Jan A. Nolta. Human CD34 + Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Equivalent Efficiency as CD34 + Cells Mobilized by G-CSF. American Society of Hematology Annual meeting, San Diego CA, abstract #1186; Blood, Dec. 2004.
133. Jesper Bonde, David A. Hess, Ryan Lahey, John F. DiPersio, Jan A. Nolta, Steven M. Devine. Multilineage Analysis of Paired AMD-3100 and G-CSF Mobilized-Peripheral Blood Stem Cell Products from Healthy Donors Undergoing Clinical Mobilization: A Pilot Study. American Society of Hematology Annual meeting, San Diego CA, abstract # 2848; Blood, Dec. 2004
134. Jesper Bonde, Phillip Herrbrich, Ryan Lahey, Jan A. Nolta. Use of Multi Color p27 kip1 Based Flow Cytometric Assay To Evaluate and Characterize G 0 to G 1 Cell Cycle Related Changes in Human Hematopoietic Cells after Subjection to a Clinically Applicable Ex Vivo Transduction Protocol. American Society of Hematology Annual meeting, San Diego CA, abstract #5283, Blood December 2004.
135. Gerhard Bauer, Jon E. Walker, Julie Ritchey, Jan A. Nolta, John F. DiPersio. GMP Scale up for a Clinical Gene Therapy Trial - High Efficiency Human T Cell Expansion and Transduction in a
51 Closed Culture System Utilizing Serum free Medium and Low IL-2 Concentrations. American Society of Hematology Annual meeting, San Diego CA, abstract # 5250, Blood Dec.2004.
136. Steven M. Devine, Jesper Bonde, David A. Hess, Terri M. Edwards, Daniel C. Link, Diane Sempek, Gary Calandra, Karin Badel, Jan A. Nolta, John F. DiPersio. A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies. American Society of Hematology Annual meeting, San Diego CA, December 2004, abstract # 3341, Blood 2004.
137. Bruno Nervi, Michael Rettig, Julie Ritchey, Jon Walker, Gerhard Bauer, Phillip Herrbrich, Jan A. Nolta, John F. DiPersio. A Murine Xenograft Model for Human T Cell Mediated Graft Versus Host Disease. American Society of Hematology Annual meeting, San Diego CA, December, abstract #4977, Blood 2004.
138. Bruno Nervi, Michael Rettig, Julie Ritchey, Jon Walker, Gerhard Bauer, Philip Herrbrich, Mark L. Bonyhadi, Jan A. Nolta, John F. DiPersio. In Vivo Suicide Gene Therapy of Human T Lymphocytes To Prevent Graft Versus Host Disease in a Murine Xenograft Model. American Society of Hematology Annual meeting, San Diego CA, December 2004, abstract # 3601.
139. David A. Hess, Timothy P. Craft, Louisa Wirthlin, Phillip E. Herrbrich, Alex A. Hofling, Mark S. Sands and Jan A. Nolta. Transplantation of Human Aldehyde Dehydrogenase Expressing Cells Leads to Widespread Tissue Distribution of Donor Cells in the Pancreas and Liver of NOD/SCID/MPSVII Mice. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, p. 178.
140. Andrew Hope, Todd E. Meyerrose and Jan A. Nolta. Retrovirally-Marked Human Bone Marrow Derived Mesenchymal Stem Cells Attenuate Radiation Induced Pneumonitis in a Xenotransplant Model. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 138.
141. Ivana Rosova and Jan A. Nolta. Human Mesenchymal and Hematopoietic Stem Cell Contribution to Cardiac Tissue Regeneration after Injury. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Pages 358-359. 142. Todd E. Meyerrose, Phillip E. Herrbrich, Michael H. Creer and Jan A. Nolta. Hepatocyte Growth Factor Maintains Hematopoietic Progenitors during Retroviral Transduction . Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, p. 399.
143. David A. Hess, Louisa Wirthlin, Timothy P. Craft, Phillip E. Herrbrich and Jan A. Nolta. Purification of Cells with High Aldehyde Dehydrogenase Activity Reveals a CD133 Negative Population with Enhanced Repopulating Ability after Ex Vivo Culture. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 398
144. Todd E. Meyerrose, Elisheva Smith, Jan A. Nolta and Baruch Frenkel. Osteogenic Growth Peptide Preferentially Enhances Trabecular Bone Mass. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 432
145. Jesper Bonde, Ryan Lahey, Phillip Herrbrich and Jan A. Nolta. Use of Multi Color p27kip1 Based Flow Cytometric Assay To Evaluate and Characterize G0 to G1 Cell Cycle Related Changes in
52 Human Hematopoietic Cells after Subjection to a Clinically Applicable Ex Vivo Transduction Protocol. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 400
146. Bruno Nervi, Michael P. Rettig, Julie K. Ritchey, Gerhard Bauer, Jon Walker, Phillip E. Herrbrich, Todd E. Meyerrose, Mark Bonyhadi, Jan A. Nolta and John F. DiPersio. Ex-Vivo Activation and Genetic Manipulation of Human T Cells Results in Consistent In-Vivo Expansion and Lethal GvHD in a Novel Murine Xenotransplant Model. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 315
147. Jesper Bonde, Dustin J. Maxwell, David A. Hess, Ryan Lahey, David Piwnica-Worms and Jan A. Nolta. Transient Transduction of Repopulating Human CD34 Cells Using Nanoparticles in a Clinically Applicable Ex Vivo Protocol. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 304
148. Todd E. Meyerrose, Phillip E. Herrbrich, Michael H. Creer and Jan A. Nolta. Adherent Human Umbilical Cord Blood Derived Mesenchymal Stem Cells Do Not Augment Viral Gene Transfer into Hematopoietic Stem/Progenitor Cells. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 401
149. Gerhard Bauer, Jon Walker, Bruno Nervi, Julie Ritchey, Jackie Hughes, Bill Eades, Mark Bonyhadi, Jan Nolta and John DiPersio. A System for GMP Expansion and Transduction of Human T Cells with High Functionality Proven by Consistent Induction of GvHD in a Mouse Xenotransplant Model. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 113
150. Phillip E. Herrbrich, Todd E. Meyerrose, Alex A. Hofling, Mark Sands and Jan A. Nolta. Transplantation of Neonatal NOD/SCID/MPSVII Mice with Human Mesenchymal Stem Cells. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 96
151. Jesper Bonde, Dustin J. Maxwell, David A. Hess, Ryan Lahey, David Piwnica-Worms and Jan A. Nolta. Differential, Transient Transduction of Defined Human Stem Cell Subsets Using Nanoparticles in a Clinically Applicable Ex Vivo Protocol. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Pages 83-84
152. Mo A. Dao and Jan A. Nolta. The Benefits of CH-296 during Ex Vivo Gene Transfer Go beyond the Ability to Co-Localize the Retroviral Particle and Target Cell. Molecular Therapy, Volume 11, Supplement 1, 15 August 2005, Page 177
153. Louisa Wirthlin, Todd E. Meyerrose, Michael H. Creer, and Jan A. Nolta. Involvement of Lipid Raft Domain Signaling in Ex Vivo Maintenance of Hematopoietic Progenitor Cells. Blood (ASH Annual Meeting Abstracts), 106: 4216. Dec 2005.
154. Todd Meyerrose, Andrew J. Hope, Shao Lin, Phillip Herrbrich, Michael Creer, and Jan A. Nolta. Tracking Differential Repopulation Kinetics of Human Hematopoietic Progenitor Cells Using MRI Detection of Nanoparticles. Blood (ASH Annual Meeting Abstracts), 106: 1274. Dec 2005.
155. Ryan Lahey, Jesper Bonde, and Jan A. Nolta. Uptake of Protamine Sulphate Complexed Fluorescent Nano-Particles Is Defined by Cell Cycle Status in Primary Human CD34+ Cells: Use
53 of a Multi-Color p27 kip1 Based Flow Cytometric Assay. Blood (ASH Annual Meeting Abstracts), 106: 1363. Dec 2005.
156. Ivana Rosova, Todd E. Meyerrose, and Jan A. Nolta. Working Toward Better Tissue Repair Therapies: Exposure of MSC to Hypoxic Conditions In Vitro Increases Levels of the Hepatocyte Growth Factor Receptor c-met, Improves Motility, and Induces Phosphorylation of the Pro- Survival Protein AKT. Blood (ASH Annual Meeting Abstracts), 106: 2313. Dec 2005.
157. David A. Hess, Louisa Wirthlin, Timothy C. Craft, Phillip E. Herrbrich, Marie Roberts, Michael H. Creer, Mark S. Sands, and Jan A. Nolta. Transplanted Human Aldehyde Dehydrogenase Expressing Stem Cells Circulate and Engraft Nonhematopoietic Tissues. Blood (ASH Annual Meeting Abstracts), 106: 1693. Dec 2005.
158. Jesper Bonde, Dustin J. Maxwell, David A. Hess, Ryan Lahey, Michael H. Creer, David Piwnica- Worms, and Jan A. Nolta. In Vivo Imaging and Tracking of Defined, Repopulating Human Stem Cell Subsets Using Fluorescence Conjugated Nanoparticles in a Clinically Applicable Ex Vivo Protocol. Blood (ASH Annual Meeting Abstracts), 106: 3031. Dec 2005.
159. David A. Hess, Louisa Wirthlin, Timothy P. Craft, Jesper Bonde, Ryan W. Lahey, Sarah A. Hohm, Phillip E. Herrbrich, John F. DiPersio, Steven M. Devine, and Jan A. Nolta. Human CD34+Cells Mobilized by AMD3100 Demonstrate Enhanced NOD/SCID Repopulating Function Compared to CD34+ Cells Mobilized by Granulocyte Colony Stimulating Factor. Blood (ASH Annual Meeting Abstracts), 106: 1962. Dec 2005.
160. Bruno Nervi, Michael P. Rettig, Julie K. Ritchey, Gerhard Bauer, Jon Walker, Dave Hess, Phillip E. Herrbrich, Mark Bonyhadi, Ronald J. Berenson, Jan A. Nolta, and John F. DiPersio. Naive and Ex Vivo Activated Human T Cells Generate Consistent Engraftment and Lethal Graft-Versus-Host Disease (GvHD) in NOD SCID ß 2M Null Mice: A New Xenogeneic Model for GvHD. Blood (ASH Annual Meeting Abstracts), 106: 3106. Dec 2005.
161. Benjamin J. Capoccia, Louisa Wirthlin, Rebecca Shepherd, Kevin O’Dell, Jan A. Nolta, Daniel C. Link, and David A. Hess. Bone Marrow-Derived Aldehyde Dehdrogenase Expressing Cells Possess Endothelial Progenitor Function in Addition to Hematopoietic Repopulating Ability and Aid in Blood Flow Recovery after Acute Ischemic Injury. Blood (ASH Annual Meeting Abstracts), 106: 2663. Dec 2005.
162. Gerhard Bauer, Jon Walker, Bruno Nervi, Julie Ritchey, Jackie Hughes, Bill Eades, Mark Bonyhadi, Jan Nolta, and John F. DiPersio. Large Scale Ex Vivo GMP Expanded, Activated Human T Cells Consistently Induce Lethal GvHD in a Mouse Xenotransplant Model - A New Way To Study Treatments for Acute GvHD. Blood (ASH Annual Meeting Abstracts), 106: 5242. Dec 2005.
163. Steven M. Devine, Leslie Andritsos, Laura Todt, Ravi Vij, Jesper Bonde, David Hess, Jan Nolta, Dan Link, Gary Bridger, Gary Calandra, and John F. DiPersio. A Pilot Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Advanced Hematological Malignancies. Blood (ASH Annual Meeting Abstracts), 106: 299, Dec, 2005.
54 164. Jesper Bonde, David A. Hess, Dustin J. Maxwell, Ryan Lahey, Michael H. Creer, David Piwnica- Worms, and Jan A. Nolta. Comparison of Human Stem Cell Homing after Intravenous or Intra- Femoral Transplantation Using Multimodal In Vivo Imaging of Repopulating Human CD34+ Cells Labeled with Far-Red Fluorescent-Conjugated Nanoparticles. Blood (ASH Annual Meeting Abstracts), 106: 2196, Dec 2005.
165. Phillip E. Herrbrich, Todd E. Meyerrose, and Jan A. Nolta. Exploring the Molecular Mechanisms for Enhancing MSC Homing and Lodgement within Sites of Liver Damage/Fibrosis. Blood (ASH Annual Meeting Abstracts), 106: 1690, Dec 2005.
166. Kathryn Crowder, Jason Brant, Junjie Chen, Anne Neubauer, Todd Meyerrose, Jan Nolta, Shelton Caruthers, Gregory Lanza, Samuel Wicklin. Unique perfluorocarbon nanobeacons improve stem/progenitor cell tracking with MRI. Presented at the Annual meeting of the American Society for Investigative Pathology, April 1, 2006
167. Gerhard Bauer, Jon Walker, Bruno Nervi, Julie Ritchey, Mike Rettig, Jackie Hughes, Bill Eades, Jan Nolta, John DiPersio. Large Scale Ex Vivo Expansion of Human T Cells under GMP Conditions Consistently Yields Fully Functional T Cells In Vivo Proven by Induction of Lethal GvHD in a Mouse Xenotransplant Model. Oral presentation, ASGT, Baltimore, MD, June 4, 2006.
168. Sarah A. Hohm, Benjamin J. Cappoccia, Louisa Wirthlin, Rebecca Shepherd, Kevin O’Dell, Jan A. Nolta, Daniel C. Link, David A. Hess. Human bone marrow-derived aldehyde dehydrogenase- expressing cells possess endothelial progenitor function and augment blood flow recovery after acute injury in a hindlimb ischemia model: working toward clinical trials. Presented at the Annual meeting of the ISSCR, Toronto, Canada July 2006.
169. David A. Hess, Louisa Wirthlin, Timothy Craft, Phillip Herrbrich, Michael Creer, Marie Roberts, Mark S. Sands, Jan A. Nolta. Transplanted human aldehyde dehydrogenase expressing stem cells demonstrate distinct engraftment characteristics in the liver and pancreas of NOD/SCID/MPSVII mice. Presented at the Annual meeting of the ISSCR, Toronto, Canada July 2006.
170. TE Meyerrose, AJ Hope, SP Lin, PE Herrbrich, MH Creer and JA Nolta. Tracking Differential Repopulation Kinetics of Human Hematopoietic Progenitors Using MRI Detection of Nanoparticle-labeled Cells. Presented at the Annual meeting of the ISSCR, Toronto, Canada July 2006.
171. Ivana Rosová and Jan A. Nolta. Hypoxia Combined with Hepatocyte Growth Factor Preconditioning of Mesenchymal Stem Cells Improves Viability and Mobility. Presented at the Annual meeting of the ISSCR, Toronto, Canada July 2006.
172. Mo A. Dao, Catherine Verfaillie, and Jan A. Nolta. Integrin engagement and osteoblast-derived cytokines are required to maintain the hematopoietic progenitor pool from cord blood in low oxygen tension, mediated through the GSK3b/beta-catenin pathway. Presented at the Annual meeting of the ISSCR, Toronto, Canada July 2006.
173. Claus Sondergaard, Dustin Maxwell, Dave Hess, Carla Weinheimer, Ivana Rosova, Michael Creer, Dave Piwnica-Worms, Attila Kovacs, Jan Nolta. Human ALDH high Stem Cells from Umbilical Cord Blood Home to the Heart after IV injection and have Therapeutic Benefit in an Immune
55 Deficient Mouse Model of Acute Myocardial Infarction. Presented at the Annual meeting of the ISSCR, Toronto, Canada July 2006.
174. Jason T. Rich, Audrey McAlinden, Ivana Rosova, Jan A. Nolta, and Linda J. Sandel. FGF-2 increases proliferation and pluripotency of human adipose-derived stem cells. Presented at the annual meeting of the American Society for Biochemistry and Molecular Biology, October 2006.
175. Kathryn Crowder, Jason Brant, Junjie Chen, Anne Neubauer, Todd Meyerrose, Jan Nolta, Shelton Caruthers, Gregory Lanza, Samuel Wickline.. Unique perfluorocarbon nanobeacons improve stem/progenitor cell tracking with MRI. Presented at the annual meeting of the American Society for Biochemistry and Molecular Biology, October 2006.
176. Louisa Wirthlin, David A. Hess, Timothy P. Craft, Phillip E. Herrbrich, Michael Creer, Marie Roberts, Mark S. Sands, Jan A. Nolta. Transplantation of human ALDH hi stem cells leads to donor cell engraftment in the liver and pancreas of NOD/SCID/MPSVII mice. Presented at the 5th Annual Gene Therapy Symposium, Sonoma, CA, Nov. 2006.
177. Anne Morawski Neubauer, Kathy Crowder, Shelton D. Caruthers, Jason Brandt, Frank D. Hockett, Jan Nolta, Gregory M. Lanza, Samuel A. Wickline, Junjie Chen. Unique and rapid 19F imaging of stem cells labeled with perfuorocarbon nanoparticles at 11.7T and 1.5T. Presented at the 2006 annual meeting of the International Society for Magnetic Resonance in Medicine, Seattle, WA.
178. Anne M. Neubauer, Kathy Partlow, Shelton D. Caruthers, Jason Brandt, Frank D. Hockett, Junjie Chen, Jan Nolta, Gregory M. Lanza, Samuel A. Wickline. Endothelial stem cell detection in vivo with unique perfluorocarbon nanoparticle labels using 19F MRI at 1.5T. Circulation 2006, 114: 251.
179. Andrew J. Hope, Strahinja Stojadinovic, Sarah Hohm, Katherine Malinowski, Kevin O’Dell, Daniel A. Low, and Jan A. Nolta. Xenografted human mesenchymal stem cells migrate to focally irradiated areas in murine lung. Presented at the Annual ASTRO meeting, November 2006.
180. Bruno Nervi, Michael P Rettig, Julie K Ritchey, Hanlin L Wang, Gerhard Bauer, Jon Walker, Phillip E. Herrbrich, Mark L Bonyhadi, Ronald J Berenson, Julie L. Prior, David Piwnica-Worms, Jan A Nolta and John F DiPersio. In vivo bioluminescence imaging (BLI) and sequential [18F]FHBG microPET imaging studies of human T cell (huT) trafficking, expansion and xenogeneic graft-versus-host-disease (X-GVHD) following different routes of T cell administration. Presented at the 2006 meeting of the American Society of Hematology, Dec 2006.
181. Kathryn C. Partlow, Jason A. Brant, Jon N. Marsh, Jan A. Nolta, Michael S. Hughes, Gregory M. Lanza, and Samuel A. Wickline. Ultrasound energy markedly and rapidly affects stem/progenitor cell labeling with nanoparticle beacons for molecular imaging and cell tracking. Presented at the 2007 meeting of the FASEB.
182. Kathryn C. Partlow, Jason A. Brant, Jon N. Marsh, Jan A. Nolta, Michael S. Hughes, Gregory M. Lanza, and Samuel A. Wickline. Ultrasound facilitates stem/progenitor cell labeling and tracking with perfluorocarbon nanobeacons via fundamental cell transport mechanisms. Presented at the 2007 meeting of the American Heart Association.
56 183. Ivana Rosova and Jan A. Nolta. Hypoxic Preconditioning Results in Increased Motility and Improved Therapeutic Potential of Human Mesenchymal Stem Cells in a Xenograft Hind Limb Ischemia Injury Model. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 217. Oral session, 2007.
184. Ping Zhou, Sara Hohm, David A. Hess, and Jan A. Nolta. Liver Engraftment by Transplanted Human Progenitor Cells with High Aldehyde Dehydrogenase Activity in a Novel Model, NOD/SCID/MPSVII Mice. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 434. Oral session, 2007.
185. Gerhard Bauer, Mo Dao, Scott Case, Todd Meyerrose, Louisa Wirthlin, Phillip Herrbrich, Ping Zhou, Xiuli Wang, Susie Csik, Jesusa Arevalo, Dianne Skelton, Jon Walker, Karen Pepper, Gay Crooks, Donald Kohn, and Jan Nolta. In Vivo Biosafety Model To Assess Risk of Adverse Events from Retroviral and Lentiviral Vectors. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2595. Poster session, 2007.
186. Claus Sondergaard, David Hess, Ivana Rosova, Sarah Hohm, Louisa Wirthlin, Ryan Lahey, Matt Lindsey, Jon Walker, Gerhard Bauer, Ping Zhou, and Jan Nolta. Adult Human Stem Cells Exert Therapeutic Effects To Repair Damaged Tissues in Xenograft Systems through Secretion of Trophic Factors Rather Than Direct Incorporation and Expansion. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 3693. Poster session, 2007.
187. Krysta D. Levac, Debra L. Robson, Marian J. Neelamkavil, Sarah A. Hohm, Benjamin J. Capoccia, Daniel C. Link, Jan A. Nolta, and David A. Hess. Aldehyde Dehydrogenase-Activity Purifies Multiple Hemangiogenic Lineages That Accelerate Vascularization of Ischemic Tissue through Paracrine Support of Neovessel Formation. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 3716. Poster session, 2007.
188. Dustin Maxwell, David Hess, Jesper Bonde, Sarah A. Hohm, Ryan Lahey, Michael Creer, David Piwnica-Worms, and Jan A. Nolta. Fluorophore Conjugated Iron Oxide Nanoparticle Labeling and Analysis of Engrafting Human Hematopoietic Stem Cells. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1213. Poster session, 2007.
189. Ping Zhou, Ryan Lahey, Sarah Hohm, Ha Tran, David Hess, PhD, Ronald Li, Jan Nolta. Liver Engraftment by Transplanted Human Cord Blood Progenitors and Human embryonic Stem Cells in a Novel Model, the NOD/SCID/MPSVII Mouse. Presented at the annual ISSCR meeting, Philiadelphia, PA, June 2008.
190. Suzanne Pontow, Matt Lindsey, Karen pepper, Louisa Wirthlin, Gerhard Bauer, Jan Nolta. Novel human stem cell populations from Wharton’s jelly. Presented at the annual ISSCR meeting, Philiadelphia, PA, June 2008.
191. Nyunt T, Huser T, Fu J, Nolta J, Rutledge J, Li R., Mapping the optical, genomic and functional signatures of endothelial progenitor cells differentiated from human embryonic stem cells. Presented at the annual ISSCR meeting, Philiadelphia, PA, June 2008.
192. Ping Zhou, PhD, Ryan Lahey, Sarah Hohm, Daniel Cortes, Yetunde Olusanya, Ha Tran, David Hess, PhD, Jan Nolta, PhD. Hepatocyte-like Cells Can Be Derived from Human Umbilical Cord
57 Blood and Embryonic Stem Cells; Tested in a Novel Mouse Model. Blood, ASH annual abstracts 2008.
193. Suzanne Pontow, Ryan Lahey, Matt Lindsey, Yetunde Olusanya, Karen Pepper, Louisa Wirthlin, and Jan Nolta. Isolation and Expansion of Cells with High Therapeutic Value from Wharton’s Jelly. Blood, ASH annual abstracts 2008.
194. Joseph S. Anderson, Jon Walker, Louisa Wirthlin, John Javien, Jan A. Nolta, and Gerhard Bauer. Evaluating the Safety and Efficacy of Anti-HIV Transgenic Cells in a Humanized Mouse Model –/– (NOD/SCIDγc ) for HIV Stem Cell Gene Therapy. Blood, ASH annual abstracts 2008.
195. J. Javien, J. Anderson, J. Walker, J. Nolta, and G. Bauer. Preclinical Evaluation of Combination Anti-HIV Lentiviral Vectors in the NOD/SCID/gamma/null Immunodeficient Mouse Model. Sonoma Gene Therapy Symposium, 2008.
196. Claus Svane Sondergaard, David Hess, Dustin Maxwell, Carla Weinheimer, Ivana Rosová, Michael Creer, Dave Piwnica-Worms, Attila Kovacs, Lene Pedersen, and Jan A. Nolta. Human Cord Blood Progenitors with High Aldehyde Dehydrogenase Activity Improve Vascular Density in a Model of Acute Myocardial Infarction. Blood, ASH annual abstracts 2008.
197. J. Anderson, J. Nolta, and G. Bauer. Safety and efficacy of lentiviral vector expressed CCR5 siRNAs in a miRNA backbone for HIV gene therapy. Sonoma Gene Therapy Symposium, 2008.
198. Fierro FA, Poitz D, Bornhäuser M, Nolta J, Ehninger G, Illmer T. MicroRNA miR-23a regulates SDF-1alphaexpression in human bone marrow-derived mesenchymal stem cells. Blood, ASH annual abstracts 2008.
199. Rosova I, Nolta J. siRNA-mediated knockdown of the c-met receptor on human mesenchymal stem cells reduces their capacity for mediating tissue repair and revascularization, Blood, ASH annual abstracts 2008.
200. Claus Sondergaard, Fernando Antonio Fierro, Jeannine McGee and Jan A. Nolta. Assessment of the Impact of Enforced Expression of Platelet Derived Growth Factor Beta in Human Mesenchymal Stem Cells and Contribution to Blood Flow Restoration. Blood, ASH annual abstracts 2009.
201. William Gruenloh, Amal Kambal, Claus Sondergaard, Jeannine McGee, Fernando Antonio Fierro, Scott Olson and Jan A. Nolta. Characterization and In Vivo Testing of Mesenchymal Stem Cells Derived From Human Embryonic Stem Cells. Blood, ASH annual abstracts 2009.
58 Chapters 1. Kohn DB, Nolta JA, Hong CM, Barranger JA. Expression of the human glucocerebrosidase gene using retroviral vectors. In Gene Transfer and Gene Therapy (UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 87). Beaudet AL, Mulligan R, Verma IM (Eds). New York: Alan R. Liss, 397-408, 1989.
2. Lenarsky C, Weinberg K, Peterson J, Nolta J, Brooks J, Annett G, Kohn D, and Parkman R. Autologous BMT with 4-hydroperoxycyclophosphamide purged marrows for children with acute nonlymphoblastic leukemia in second remission In Autologous Bone Marrow Transplantation. Dicke KA, Armitage JO, Dicke-Evinger MJ (eds). pp 105-112, 1990.
3. Nolta JA and Kohn DB. Hematopoietic stem cells for gene therapy. In Stem Cell Handbook, Edited by C. S. Potten, Academic Press Limited, London, UK. Pages 447-461, 1996.
4. Dao MA and Nolta JA. An in vivo system to trace the progeny of transduced pluripotent human hematopoietic stem cells. Published in the Manual for the American Society of Blood and Marrow Transplantation (ASBMT), distributed at the Scientific Meeting in San Diego, CA, October 1996.
5. Dao MA and Nolta JA. A system to measure the extent of human hematopoietic stem cell marking by retroviral vectors. Published in the Syllabus for the 5th International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation-Clinical Progress, New Technologies and Gene Therapy, distributed at the Annual Meeting of the International Society for Hematotherapy and Graft Engineering (ISHAGE) in Mission Bay, April, 1997.
6. Dao MA and Nolta JA. Retroviral - mediated transduction of human hematopoietic stem and progenitor cells measured in a long-term xenograft assay. European Society of Hematology Teaching Manual, Plenum Press, 1997.
7. Nolta JA, and Kohn DB. Human hematopoietic cell culture, transduction, and analyses. “Current Protocols in Human Genetics”, John Wiley and Sons, Inc. Chapter 13, Unit 13.7, 1997.
8. Dao MA and Nolta JA. The effects of ex-vivo manipulation on the differentiation of human hematopoietic stem cells. Teaching Manual for the Annual Meeting of the American Association of Blood Banks, AABB Press, Chapter 4, 12110-12135, 1998.
9. Kohn DB, Nolta JA, Crooks GM. Clinical trials of gene therapy using hematopoietic stem cells. Hematopoietic Cell Transplantation, 2nd edition. Edited by Forman S, Blume K, Thomas ED. Blackwell Scientific Publications, Boston, MA. Chapter 11; Pages 97-102, 1999.
10. Kohn DB, Scheuning F, Dunbar C, Pensiero M, Kiem HP, Beach K, Zaboikin M, Miller D, Storb R, Wells S, Nolta J, Esplin J, Barton N, Brady R, and Karlsson S. Early trials of gene transfer for Gaucher Disease. Advances in Jewish Genetic Diseases, 2001.
11. Kohn DB, Crooks GM, Nolta JA. Gene therapy using hematopoietic stem cells. Hematopoietic stem cell therapy, Ed.s: AD Ho and RE Champlin. Cambridge University Press, 2001.
12. Dao MA and Nolta JA. An increase in the levels of retroviral - mediated transduction of engrafting human hematopoietic progenitors can be obtained by manipulation of the hematopoietic cell cycle.
59 Molecular Biology of Hematopoiesis VI, Edited by Abraham et al., Plenum Publishers, NY 2001.
13. Kohn DB, Crooks GM, Nolta JA, Kapoor N, Weinberg K, and Parkman, R. Gene therapy with cord blood hematopoietic stem cells. Immunologic function of cord blood hematopoietic stem cells. Ed Paul McCurdy, M.D., Marcel Dekker Inc, New York. 2001.
12. Dao MA, Nolta JA. Retroviral - mediated transduction of human hematopoietic stem and progenitor cells. Hematopoietic Stem Cell Protocols, Chapter 17, P. 253-274. Editors. C. Jordan and C. Klug. The Humana Press Inc., Totowa, NJ 2002.
13. Meyerrose TM, Herrbrich P, Wang X, Dao MA, Nolta JA. Pluripotent human stem cell analysis in immune deficient mice. The Pluripotential Hematopoietic Stem Cell, Editor: J. Keller. Eurekah Press, Chapter 4, 2003.
14. Nolta J, Bauer G, and Sands M. Animal models for clinical gene therapy trials. In Translational and Experimental Clinical Research. Philadelphia: Lippincott Williams & Wilkins; Schuster, Daniel P. and William J. Powers, eds. 2005.
15. Meyerrose TM, Rosova I, Dao MA, Herrbrich P, Bauer G, and Nolta JA. Establishment and transduction of primary human stromal/ mesenchymal stem cell monolayers. Chapter 2, Genetic Engineering of Mesenchymal Stem Cells. Kluwer Academic Publishers, Dordrecht, the Netherlands. Nolta JA (Editor). February 2006.
16. Jesper Bonde, Donald B. Kohn, and Jan A. Nolta. Human Hematopoietic Cell Culture, Transduction, and Analyses. Current Protocols in Human Genetics. Chapter 13, 2008.
17. Ping Zhou, Sarah Hohm, Ben Capoccia, Dan Link, and Nolta JA. Immunodeficient mouse models to study human stem-cell mediated repair of tissue injury. Hematopoietic Stem Cell Protocols: Second Edition, Methods in Molecular Medicine, The Humana Press Inc., edited by Kevin Bunting. 2008.
18. Joyce, Olson, Annett, Bauer, Nolta. Human Mesenchymal stem cells as therapeutics for neurodegenerative diseases. In preparation, Future Medicine 2010
60 Director’s Statement
Since joining the faculty of UC Davis as director of the Stem Cell Program in 2006, my primary missions have been to 1) foster teamwork, 2) to increase multidisciplinary training opportunities, 3) to assist in development of junior faculty affiliated with the program, 4) to help provide a new building for the program, and 5) to help build and promote Disease Teams, working toward initiating clinical trials of cellular therapies.
My key goals for the next two years are 1) to further develop the multidisciplinary Stem Cell Program in the new “Institute for Regenerative Cures” building, 2) to include as many of the great strengths and key faculty on our campus as possible in moving forward toward increased funding, especially program project funding, 3) to develop and fund novel, cutting edge training programs in Cellular Therapies and Good Manufacturing Practices, and 4) to initiate clinical trials of cellular therapies, which are now pending for four of our disease teams. My primary goal during the first three years of my position has been to help to further enhance public perception of Stem Cell Research at UC Davis, to let as many other sites as possible know about the great work that has been going on here for many years, and will continue to proceed at an accelerated fashion, through enhanced teamwork in the new collaborative Institute for Regenerative Cures, with renovation newly completed, at the corner of Stockton and Broadway.
There are over 145 faculty members now affiliated with the stem cell program, through many disciplines throughout both campuses, working in 15 disease teams; 1) Liver repair and regeneration, bioengineered livers, 2) Peripheral artery disease: revascularization to prevent amputation, 3) Eye degeneration/blindness, 4) Lung disease, lung repair and regeneration, 5) Skin: Non-healing ulcers, burn repair, 6) Blood Disorders, leukemia and lymphoma, autoimmunity, 7) Bone repair, osteoporosis, cartilage regeneration, 8) Heart disease, infarction repair, 9) HIV; Engineering of resistance in blood and mucosa, 10) Neurodegenerative diseases (Parkinson’s, Huntington’s, Alzheimers), 11) Kidney repair and regeneration, 12) Bladder repair, bioengineered bladders, 13) Hearing, inner ear cilia repair, 14) Tumor stem Cells, Cell-based immunotherapy for Cancer, 15) Neurodevelopmental disorders. In each team we have basic, translational and clinical faculty working together toward the common goal of using stem cell therapies to cure or alleviate the respective disease or injury, or to use induced pluripotent stem cells from the patient to learn more about how to use conventional medicines to better treat the disease.
In addition to training, my primary mission continues to be to foster interactions between pre-existing UC Davis faculty members and programs and national and international collaborators, to recruit and retain excellent junior faculty members, and to enhance research and public perception by achieving scientific excellence in all areas of the Stem Cell Program.
The first logistical missions that I had in setting up the new program were to acquire, set up, and staff a flow sorter, a mouse irradiator, and an immune deficient mouse core for the affiliated members of the Stem Cell Program and others on the Sacramento campus. Since embryonic stem cells, primary tumor tissues, and some types of primary adult stem cells do not dissociate and travel well, it is vital to have these resources available on the Sacramento campus, for researchers who work there, and for collaborative teams using discarded patient samples there. I have worked with immune deficient mouse models to study the engraftment of human stem cells for 20 years, and we brought unique models to UC Davis, now set up as a xenotransplantation core with mouse irradiator in the Research III building. There is a Cytopeia Influx high speed,
61 multi-color cell sorter in the Oak Park Research Building, available to all investigators through the Optical Biology website and core recharges.
We have used the expertise of the team that relocated with me, and our unique sorting strategies and immune deficient mouse models of injury and disease, to work directly with investigators to generate key pieces of preliminary data to help them to be more competitive for future stem cell grant funding. This strategy allows training of students and technicians to take the methods back to their own labs. Our weekly Monday morning group meetings (9:30-11:30) have an average of 20 students from different groups attending, to discuss progress or problems with their data. I also meet individually with students and junior faculty members continually throughout the week, and do over 95% of my own work at home at night.
The Stem Cell Program group of key personnel that we have assembled is very collaborative, and is organized by Disease Team or core (immune deficient mouse, embryonic stem cell, adult stem cell, tumor stem cell, microscopy, FACS, and vector cores). Each bench is labeled by team or core, and has a key program contact person working there, plus various trainees or investigators rotating through from other groups. This setup will be duplicated, on a larger scale, in the new “Institute for Regenerative Cures”, under renovation at the corner of Stockton and Broadway. This building will be the central hub for Stem Cell Research on the Sacramento Campus. Writing the application to the California Institute for Regenerative Medicine (CIRM), and understanding the unique talents presented by each faculty member, and how all of the work integrated into the “big picture” of UC Davis was my primary focus during my first year. The application was written with Dr. Tarantal, and with assistance from Gerhard Bauer, the CTSC, and the input from many faculty members for the first phase, submitted in October, 2007. We were judged to be competitive to go forward to apply for an “institute”, with basic, translational, and clinical components, by the CIRM oversight committee. This was an honor since only seven were selected in this category throughout California, out of 17 applications submitted. The Part II application (facility design, building details, blueprints, etc) was then written by Mark Romney and Mike Boyd, and the entire facilities team, with text provided by me and Dr. Tarantal. We were awarded just over $20 million dollars to help build this institute. The groundbreaking was held September 26th, and some of the laboratories, including the state of the art “Good Manufacturing Laboratory” will open in late 2009. This facility will further foster collaborative interactions through its “open door” policy, interactive colleagues, proximity to the CTSC and wide range of experienced stem cell investigators that will be housed there.
One of the most exciting things about the new facility, and our capacity to take stem cell therapies from the bench through translational studies and toxicology testing, then into clinical trials in one building, will be the increased opportunities for training. I am deeply committed to teaching and training students and, since coming to Davis, have worked on developing two novel programs, which are in the process of having funding secured. The first is an NIH T-35: Introduction to Cellular Therapy for Students in Health Care Professions. The goal of the T-35 will be to give students an introduction to the components involved in moving promising research from the bench to the bedside. This will be a new 6-week training program for medical and other health care students in between their first and second years. It will include lectures from, and shadowing opportunities with stem cell program members involved in cellular therapy trials.
The second is the “Bridges” training Program with California State University, Sacramento,
62 currently under consideration for funding by the California Institute for Regenerative Medicine. The goal of this program is for UC Davis and CSUS to jointly train diverse groups of promising students for health care professional careers. Drs. Nolta and Bauer are developing a Good Manufacturing Practice and cellular therapy course in collaboration with CSUS. Dr. Nolta has identified 29 mentors in the UC Davis Stem Cell Program who are eager to train CSUS interns, to allow them to have on the-job training.
My own NIH-funded research revolves around trying to answer the question of how stem cells infused IV are recruited to sites of tissue damage. So far we know that in some types of damage, such as heart attack and the peripheral limb damage that can happen in diabetes, that signals for recruitment of the cells are initiated by a lack of oxygen. We are studying these signals after tissue damage in mice to see how the human cells are recruited to that area and to learn what they do once they get there. We are using sophisticated assays to understand how the cells change once they get to the site of damage. By understanding the fine details of these processes for adult stem cells we can better learn how to use them in regenerative medicine, to make the repair quicker and more robust, and we are now applying this knowledge to embryonic stem cells and induced pluripotent stem cells.
My laboratory works in translational biology at the GLP, or “good laboratory practice” level, required to take gene therapy and tissue repair studies from the bench into the clinic. In addition to training students, teaching didactic courses and presenting stem cell-related educational lectures in multiple divisions at the three Universities where I have worked, I have given many grand rounds overviews on my field in invited lectures at other Universities, have been an invited speaker in many symposia and international meetings, and have also done a large amount of public outreach lecturing to educate lay people about stem cells, the potential uses, and the differences between embryonic and adult stem cells. The lectures have been at churches, zoos, technology centers, science centers, high schools, and even rotary clubs. I feel that the education of our community members in stem cell-related issues is extremely important, since these therapies could be beneficial to them or to their families in the future. People are also fascinated by these issues and by the new technologies available, and it is exciting to bring them the knowledge that they seek.
I am honored to be chosen for a leadership role in this program, and to be a part of the rapidly developing new technologies at UCD. What we are particularly excited about is the ability in California to compare the adult stem cells to human embryonic stem cells. One cell type cannot do it all. There will be different types and isolation strategies required for the repair of each tissue in the human body that can become damaged or diseased. My inspiration is the desire to help people of all ages and backgrounds, who have damage to or inherited effects in various organs. Stem cells are a part of the body’s own natural repair system, and it is fascinating to learn how they are mobilized to sites of damage, and to learn more and more each day in the laboratory to define ways that we can better manipulate these natural processes to allow improved regenerative medicine applications. The processes of regulation in the stem cell’s journey to a site of injury are endlessly fascinating to me. In regards to teaching, I am excited by sharing what we learn from the stem cells with other scientists, students, and the public. It is a truly inspiring area and the benefits for the health and medical treatment of children and adults are immeasurable.
63